AU6497998A - 2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivatives - Google Patents
2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivativesInfo
- Publication number
- AU6497998A AU6497998A AU64979/98A AU6497998A AU6497998A AU 6497998 A AU6497998 A AU 6497998A AU 64979/98 A AU64979/98 A AU 64979/98A AU 6497998 A AU6497998 A AU 6497998A AU 6497998 A AU6497998 A AU 6497998A
- Authority
- AU
- Australia
- Prior art keywords
- dichlorobenzoyl
- cyclopropane
- carboxylic acid
- carboxylate
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 description 115
- -1 on the one side Chemical compound 0.000 description 77
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 42
- 239000000203 mixture Substances 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- 229910052739 hydrogen Inorganic materials 0.000 description 26
- 239000001257 hydrogen Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 125000003545 alkoxy group Chemical group 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 18
- 238000003760 magnetic stirring Methods 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 12
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 108010033242 Kynurenine 3-monooxygenase Proteins 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 102100037652 Kynurenine 3-monooxygenase Human genes 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 9
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 9
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- VCKPUUFAIGNJHC-UHFFFAOYSA-N 3-hydroxykynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC(O)=C1N VCKPUUFAIGNJHC-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 239000012300 argon atmosphere Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 5
- WJXSWCUQABXPFS-UHFFFAOYSA-N 3-hydroxyanthranilic acid Chemical compound NC1=C(O)C=CC=C1C(O)=O WJXSWCUQABXPFS-UHFFFAOYSA-N 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- JFJFPXNBPGWPNH-UHFFFAOYSA-N 2-(3,4-dichlorobenzoyl)-3-methylcyclopropane-1-carboxylic acid Chemical compound CC1C(C(O)=O)C1C(=O)C1=CC=C(Cl)C(Cl)=C1 JFJFPXNBPGWPNH-UHFFFAOYSA-N 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000002532 enzyme inhibitor Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- ASDRQRUNZNMBAM-ZROIWOOFSA-N (4z)-4-[2-(3,4-dichlorophenyl)-2-oxoethylidene]-2-phenyl-1,3-oxazol-5-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)\C=C/1C(=O)OC(C=2C=CC=CC=2)=N\1 ASDRQRUNZNMBAM-ZROIWOOFSA-N 0.000 description 3
- HJIVSCXTCIZJQA-UHFFFAOYSA-N 2-(3,4-dichlorobenzoyl)-3-methylidenecyclopropane-1-carboxylic acid Chemical compound C=C1C(C(=O)O)C1C(=O)C1=CC=C(Cl)C(Cl)=C1 HJIVSCXTCIZJQA-UHFFFAOYSA-N 0.000 description 3
- YTTAYDFQLSNHHN-UHFFFAOYSA-N 2-(3,4-dichlorobenzoyl)cyclobutane-1-carboxylic acid Chemical compound OC(=O)C1CCC1C(=O)C1=CC=C(Cl)C(Cl)=C1 YTTAYDFQLSNHHN-UHFFFAOYSA-N 0.000 description 3
- JBIPDCOYYLUUBX-UHFFFAOYSA-N 2-(3,4-difluorobenzoyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)C1CC1C(=O)C1=CC=C(F)C(F)=C1 JBIPDCOYYLUUBX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 229940125532 enzyme inhibitor Drugs 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- ASDRQRUNZNMBAM-UHFFFAOYSA-N (4E)-4-[2-(3,4-dichlorophenyl)-2-oxoethylidene]-2-phenyl-1,3-oxazol-5-one Chemical compound C1(=CC=CC=C1)C=1OC(C(N1)=C/C(C1=CC(=C(C=C1)Cl)Cl)=O)=O ASDRQRUNZNMBAM-UHFFFAOYSA-N 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- ZBRKMOHDGFGXLN-UHFFFAOYSA-N 2-(3,4-dichlorobenzoyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)C1CC1C(=O)C1=CC=C(Cl)C(Cl)=C1 ZBRKMOHDGFGXLN-UHFFFAOYSA-N 0.000 description 2
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 description 2
- LSYDATLNOABMJD-UHFFFAOYSA-N 3-(3,4-dichlorobenzoyl)-2,2-difluorocyclopropane-1-carboxylic acid Chemical compound FC1(F)C(C(=O)O)C1C(=O)C1=CC=C(Cl)C(Cl)=C1 LSYDATLNOABMJD-UHFFFAOYSA-N 0.000 description 2
- LZXZDLJRRHTOOA-UHFFFAOYSA-N 3-(3,4-dichlorobenzoyl)-2,2-dimethylcyclopropane-1-carboxylic acid Chemical compound CC1(C)C(C(O)=O)C1C(=O)C1=CC=C(Cl)C(Cl)=C1 LZXZDLJRRHTOOA-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- HDVJZIWTSHYFQC-NTEUORMPSA-N (4E)-4-[2-(3,4-difluorophenyl)-2-oxoethylidene]-2-phenyl-1,3-oxazol-5-one Chemical compound c1c(F)c(F)ccc1C(=O)\C=C1\N=C(c2ccccc2)OC1=O HDVJZIWTSHYFQC-NTEUORMPSA-N 0.000 description 1
- HDVJZIWTSHYFQC-ZROIWOOFSA-N (4Z)-4-[2-(3,4-difluorophenyl)-2-oxoethylidene]-2-phenyl-1,3-oxazol-5-one Chemical compound c1c(F)c(F)ccc1C(=O)\C=C1/N=C(c2ccccc2)OC1=O HDVJZIWTSHYFQC-ZROIWOOFSA-N 0.000 description 1
- WKFJJLCNKCTLGD-GXDHUFHOSA-N (4e)-4-[2-(3-bromophenyl)-2-oxoethylidene]-2-phenyl-1,3-oxazol-5-one Chemical compound BrC1=CC=CC(C(=O)\C=C\2C(OC(=N/2)C=2C=CC=CC=2)=O)=C1 WKFJJLCNKCTLGD-GXDHUFHOSA-N 0.000 description 1
- ZHXSNAIEXHZZLO-GXDHUFHOSA-N (4e)-4-[2-(3-chlorophenyl)-2-oxoethylidene]-2-phenyl-1,3-oxazol-5-one Chemical compound ClC1=CC=CC(C(=O)\C=C\2C(OC(=N/2)C=2C=CC=CC=2)=O)=C1 ZHXSNAIEXHZZLO-GXDHUFHOSA-N 0.000 description 1
- MPDUTKKYSFEICL-GXDHUFHOSA-N (4e)-4-[2-(3-fluorophenyl)-2-oxoethylidene]-2-phenyl-1,3-oxazol-5-one Chemical compound FC1=CC=CC(C(=O)\C=C\2C(OC(=N/2)C=2C=CC=CC=2)=O)=C1 MPDUTKKYSFEICL-GXDHUFHOSA-N 0.000 description 1
- WKFJJLCNKCTLGD-UVTDQMKNSA-N (4z)-4-[2-(3-bromophenyl)-2-oxoethylidene]-2-phenyl-1,3-oxazol-5-one Chemical compound BrC1=CC=CC(C(=O)\C=C/2C(OC(=N\2)C=2C=CC=CC=2)=O)=C1 WKFJJLCNKCTLGD-UVTDQMKNSA-N 0.000 description 1
- MPDUTKKYSFEICL-UVTDQMKNSA-N (4z)-4-[2-(3-fluorophenyl)-2-oxoethylidene]-2-phenyl-1,3-oxazol-5-one Chemical compound FC1=CC=CC(C(=O)\C=C/2C(OC(=N\2)C=2C=CC=CC=2)=O)=C1 MPDUTKKYSFEICL-UVTDQMKNSA-N 0.000 description 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- IJXJGQCXFSSHNL-QMMMGPOBSA-N (R)-(-)-2-Phenylglycinol Chemical compound OC[C@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-QMMMGPOBSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- WBPAOUHWPONFEQ-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C(Cl)=C1 WBPAOUHWPONFEQ-UHFFFAOYSA-N 0.000 description 1
- GZVMFSAUHKADTG-UHFFFAOYSA-N 1-(3-chlorophenyl)prop-2-en-1-one Chemical group ClC1=CC=CC(C(=O)C=C)=C1 GZVMFSAUHKADTG-UHFFFAOYSA-N 0.000 description 1
- YNEBLGHWBGZEHR-UHFFFAOYSA-N 1-amino-2-(3,4-dichlorobenzoyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(N)CC1C(=O)C1=CC=C(Cl)C(Cl)=C1 YNEBLGHWBGZEHR-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IEJPPSMHUUQABK-UHFFFAOYSA-N 2,4-diphenyl-4h-1,3-oxazol-5-one Chemical compound O=C1OC(C=2C=CC=CC=2)=NC1C1=CC=CC=C1 IEJPPSMHUUQABK-UHFFFAOYSA-N 0.000 description 1
- KPAQQHZLZRWKBB-UHFFFAOYSA-N 2-(3,4-dichlorobenzoyl)-n-hydroxycyclopropane-1-carboxamide Chemical compound ONC(=O)C1CC1C(=O)C1=CC=C(Cl)C(Cl)=C1 KPAQQHZLZRWKBB-UHFFFAOYSA-N 0.000 description 1
- DNGSLZLFPSGCQH-UHFFFAOYSA-N 2-(3,4-dichlorobenzoyl)cyclopentane-1-carboxylic acid Chemical compound OC(=O)C1CCCC1C(=O)C1=CC=C(Cl)C(Cl)=C1 DNGSLZLFPSGCQH-UHFFFAOYSA-N 0.000 description 1
- SNVJBFKKUMRVTM-UHFFFAOYSA-N 2-(3,4-dichlorobenzoyl)cyclopropane-1-carboxamide Chemical compound NC(=O)C1CC1C(=O)C1=CC=C(Cl)C(Cl)=C1 SNVJBFKKUMRVTM-UHFFFAOYSA-N 0.000 description 1
- MDMMYRFYWOFYSV-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2-oxoacetaldehyde Chemical compound ClC1=CC=C(C(=O)C=O)C=C1Cl MDMMYRFYWOFYSV-UHFFFAOYSA-N 0.000 description 1
- VZRYIZGMQICGSF-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-2-oxoacetaldehyde Chemical compound FC1=CC=C(C(=O)C=O)C=C1F VZRYIZGMQICGSF-UHFFFAOYSA-N 0.000 description 1
- DJRPLSCYUZAEQB-UHFFFAOYSA-N 2-(3-bromobenzoyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)C1CC1C(=O)C1=CC=CC(Br)=C1 DJRPLSCYUZAEQB-UHFFFAOYSA-N 0.000 description 1
- ANVCBQQMGRYOGJ-UHFFFAOYSA-N 2-(3-bromophenyl)-2-oxoacetaldehyde Chemical compound BrC1=CC=CC(C(=O)C=O)=C1 ANVCBQQMGRYOGJ-UHFFFAOYSA-N 0.000 description 1
- QFHJDEIRMZKFIP-UHFFFAOYSA-N 2-(3-chlorobenzoyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)C1CC1C(=O)C1=CC=CC(Cl)=C1 QFHJDEIRMZKFIP-UHFFFAOYSA-N 0.000 description 1
- SQTOBAAJPRCLLI-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-oxoacetaldehyde Chemical compound ClC1=CC=CC(C(=O)C=O)=C1 SQTOBAAJPRCLLI-UHFFFAOYSA-N 0.000 description 1
- UUMDEUZXEMIWBF-UHFFFAOYSA-N 2-(3-fluorobenzoyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)C1CC1C(=O)C1=CC=CC(F)=C1 UUMDEUZXEMIWBF-UHFFFAOYSA-N 0.000 description 1
- XZOVDWQTSXDMBZ-UHFFFAOYSA-N 2-(3-fluorophenyl)-2-oxoacetaldehyde Chemical compound FC1=CC=CC(C(=O)C=O)=C1 XZOVDWQTSXDMBZ-UHFFFAOYSA-N 0.000 description 1
- VPHHJAOJUJHJKD-UHFFFAOYSA-N 3,4-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C(Cl)=C1 VPHHJAOJUJHJKD-UHFFFAOYSA-N 0.000 description 1
- PBOOZQFGWNZNQE-UHFFFAOYSA-N 3-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Br)=C1 PBOOZQFGWNZNQE-UHFFFAOYSA-N 0.000 description 1
- WHIHIKVIWVIIER-UHFFFAOYSA-N 3-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1 WHIHIKVIWVIIER-UHFFFAOYSA-N 0.000 description 1
- SYVNVEGIRVXRQH-UHFFFAOYSA-N 3-fluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1 SYVNVEGIRVXRQH-UHFFFAOYSA-N 0.000 description 1
- 102100029016 3-hydroxyanthranilate 3,4-dioxygenase Human genes 0.000 description 1
- 108010072768 3-hydroxyanthranilate 3,4-dioxygenase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229940122439 Hydroxylase inhibitor Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 108010031676 Kynureninase Proteins 0.000 description 1
- 108010068073 Kynurenine-oxoglutarate transaminase Proteins 0.000 description 1
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- NOVBSBMOCRGDQF-UHFFFAOYSA-N [1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopropanecarbonyl] 3,4-dichlorobenzoate Chemical compound ClC=1C=C(C(=O)OC(=O)C2(CC2)NC(=O)OC(C)(C)C)C=CC=1Cl NOVBSBMOCRGDQF-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 238000005888 cyclopropanation reaction Methods 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- JBVOSZYUSFDYIN-UHFFFAOYSA-N dimethyl cyclopropane-1,2-dicarboxylate Chemical compound COC(=O)C1CC1C(=O)OC JBVOSZYUSFDYIN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 102000005447 kynureninase Human genes 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000003870 salicylic acids Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/18—Saturated compounds containing keto groups
- C07C62/20—Saturated compounds containing keto groups with a saturated six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/38—Unsaturated compounds containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
2-SUBSTITUTED BENZOY -CYC OALKYL-1-CARBOXY IC ACID DERIVATIVES
The present invention relates to 2- (substituted" benzoyl)- cycloalkyl-1-carboxylic acid derivatives, to a process for their preparation, to pharmaceutical compositions containing them and to their use in therapy.
The compounds of the invention act as inhibitors of Kynurenine- 3-hydroxylase (KYN-OH) , an enzyme which forms part of the metabolic pathway of kynurenine.
It is well known that through the kynurenine pathway, tryptophan metabolism gives rise to the formation of 3- hydroxykynurenine (3-OHKYN) and quinolinic acid (QUIN), on the one side, and kynurenic acid (KYNA) , on the other side, as shown in Figure 1. (The legend to Figure 1 is to be found on the last page of the experimental part of the specification) . KYNA is endowed with neuroprotective properties (J. Neurosci. 1990,10,2965-2973), whereas QUIN is a potent neurotoxin which has been implicated in the pathogenesis of a variety of neurological disorders (Life Sci. 1984,35,19-32; Nature, 1986,321,168-171; Science, 1983,219,316-318).
Increased concentrations of QUIN have also been indicated as responsible for neurological disorders accompanying many infections and inflammatory diseases including Acquired Immunodeficiency Syndrome (AIDS) (Ann. Neurol . 1991,29,202- 209) .
One of the main strategies, aimed at altering the KYNA/QUIN balance blocking 3-OHKYN and QUIN production and increasing KYNA production, entails inhibition of key enzymes of the kynurenine (KYN) pathway, among which Kynurenine-3 -hydroxylase is of primary importance.
Consequently, there is a need in therapy of compounds able of inhibiting this enzyme.
The compounds of the present invention fulfill such a need.
Accordingly, the present invention provides 2- (substituted benzoyl) -cycloalkyl-1-carboxylic acid compounds of formula (I)
wherein E is a C1-C4 alkylene chain, in which a carbon atom is optionally substituted by =CH2, one or two C^C^ alkyl groups or one or two halogen atoms; each of R and R17 being the same or different, is hydrogen, halogen, hydroxy, trifluoromethyl , cyano, nitro, phenyl, benzyl, C^Cg alkyl, C^Cg alkoxy, C1-C6 alkylthio, SOR4 or S02R4 in which R4 is C1-C6 alkyl or -N(R5R6) in which each of R5 and Rr is, independently, hydrogen, CACg alkyl, formyl or C -C«- alkanoyl ; R2 is hydrogen or -N(R7R8) in which each of R7 and Rs is, independently, hydrogen, C-L-Cg alkyl, benzyl, phenyl, hydroxy, C^Cg alkoxy, benzyloxy or one of R7 and R8 is hydrogen and the other is C0R9 in which R9 is hydrogen, C-^-Cg alkyl, C-L-Cg alkoxy, phenyl or R9 is a group -N(R10Rι:L) in which each of R10 and Rlλ is independently hydrogen or C Cg alkyl; R3 is hydroxy, C-L-Cg alkoxy, phenoxy, benzyloxy or a group -N(R12R13) wherein R12 and R13 are as R7 and R8 as defined above, or one of R12 and R13 is hydrogen and the other is a S02R9 group in which R9 is as defined above; and pharmaceutically acceptable salts thereof .
The alkyl and alkoxy groups may be branched or straight groups . E as a Cλ-C4 alkylene chain is preferably a C^C;, alkylene chain, in particular a methylene (-CH2-) group. When such alkylene chain is substituted, it is preferably substituted by a =CH2 group or one or two halogen atoms, in particular fluorine or one or two methyl groups.
Representative examples of Cx-C6 alkyl groups include C1-C4 alkyl groups such as methyl, ethyl, n- and iso-propyl, n- , iso- , sec- and tert-butyl. Representative examples of j^-Cg alkoxy groups include Cλ - C, alkoxy groups such as methoxy and ethoxy.
Representative examples of C1-C6 alkylthio groups include C1-C4 alkylthio groups such as methylthio and ethylthio. Representative examples of C-^Cg alkanoyl groups include C1-C4 alkanoyl groups such as acetyl and propionyl .
Representative examples of C-L-Cg alkoxycarbonyl groups include C1-C4 alkoxycarbonyl groups such as methoxycarbonyl and ethoxycarbonyl . A halogen atom is fluorine, bromine, chlorine or iodine; in particular chlorine or fluorine.
Pharmaceutically acceptable salts of the compounds of the invention include acid addition salts with inorganic, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric and phosphoric acids or organic, e.g. acetic, trifluoroacetic , propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic and salicylic acids, and salts with inorganic, e.g. alkali metal, especially sodium or potassium bases or alkaline-earth metal, especially calcium or magnesium bases, or with organic bases, e.g. acyclic or cyclic amines, preferably methylamine, ethylamine, diethlamine, triethylamine or piperidine.
The compounds of the invention have asymmetric carbon atoms and therefore they can exist either as racemic mixtures or as individual optical isomers (enantiomers) . Moreover the compounds of the invention can also be E- or Z- isomers or E-, Z- mixtures thereof.
Accordingly the present invention also include within its scope all the possible isomers and their mixtures and both the metabolites and the pharmaceutically acceptable bio-precursors
(otherwise known as pro-drugs) of the compounds of the invention.
Preferred compounds of the invention are the compounds of formula (I) wherein:
E is a -CH2- or a -(CH2)2- group, optionally substituted by =CH2, one or two halogen atoms or one or two Cx-C4 alkyl groups; each of R and Rx , being the same or different, is hydrogen, halogen, hydroxy, trifluoromethyl , cyano, nitro, Cx-C4 alkyl, C-L-Qi alkoxy, C1-C4 alkylthio, S0R4 , S02R4 in which P4 is CAOj alkyl or -N(R5R6) in which each of R5 and R6 is, independently, hydrogen, C1-C4 alkyl or ormyl ; R2 is hydrogen or -N(R7R8) m which each of R7 and R8 is, independently, hydrogen, CX-CΛ alkyl, benzyl, phenyl, hydroxy, C-L-C4 alkoxy or benzyloxy, or one of R7 and R8 is hydrogen and the other is C0R9 in which R9 is hydrogen, C1-C4 alkyl, A-^ alkoxy, phenyl or R9 is a group -N(R10R11) in which R10 and RX1 is, independently, hydrogen or C1-C4 alkyl;
R3 is hydroxy, C-L-CJ alkoxy, benzyloxy, hydroxylamino or a group -N(R12R13) wherein one of R12 and R13 is hydrogen and the other is hydrogen, CX- C alkyl, benzyl, phenyl or a S02R9 group in which R9 is phenyl; and the pharmaceutically acceptable salts thereof.
More preferred compounds according to the invention are the compounds of formula (I) wherein:
E is methylene, optionally substituted by =CH2, one or two halogen atoms or one or two C^^ alkyl groups; each of R and Rλ , being the same or different, is hydrogen or halogen; R2 is hydrogen;
R3 is hydroxy, C^C,, alkoxy, hydroxylamino or a group -N(R12R13) wherein one of R12 and R13 is hydrogen and the other is hydrogen, ^^- ^ alkyl, benzyl, phenyl cr a S02R9 group in which
R9 is phenyl; and the pharmaceutically acceptable salts thereof.
Most preferred compounds according to the invention are the compounds of formula (I) wherein:
E is methylene, optionally substituted by =CH2, one or two halogen atoms or one or two C]_-C4 alkyl groups; R and R1 are both halogen;
R2 is hydrogen;
R3 is hydroxy, C - C4 alkoxy, hydroxylamino or a group -N(R12R13) wherein one of R12 and R13 is hydrogen and the other is hydrogen, C-L - C, alkyl, benzyl, phenyl or a S02R9 group in which R9 is phenyl; and the pharmaceutically acceptable salts thereof.
Examples of preferred compounds of the invention are the following :
2- (3 -chlorobenzoyl) -cyclopropane-1-carboxylic acid; 2- (3-fluorobenzoyl) -cyclopropane-1-carboxylic acid; 2- (3 -bromobenzoyl) -cyclopropane- 1-carboxylic acid; 2- (3 , 4 -dichlorobenzoyl ) -cyclopropane-1-carboxylic acid; 2- (3,4 -difluorobenzoyl) -cyclopropane- 1-carboxylic acid; 2- (3,4 -dichlorobenzoyl) -l-amino-cyclopropane- 1-carboxylic acid; 2- (3 , 4 -dichlorobenzoyl) -3 -methylene-cyclopropane- 1-carboxylic acid;
2- (3 , 4 -dichlorobenzoyl) -3 , 3 -dimethyl-cyclopropane- 1-carboxylic acid;
2- (3 , 4 -dichlorobenzoyl) -3 , 3 -difluoro-cyclopropane- 1-carboxylic acid; 2- (3 , 4 -dichlorobenzoyl) -3 -methyl -cyclopropane-1-carboxylic acid;
2- (3 , 4 -dichlorobenzoyl) -eyelopentane- 1-carboxylic acid; 2- (3 , 4 -dichlorobenzoyl) -cyclopropane-1-carboxamide ; 2- (3 , 4-dichlorobenzoyl) -cyclopropane-1-N-methyl-carboxamide 2- (3 , 4 -dichlorobenzoyl) -cyclopropane- 1-N-benzyl -carboxamide , 2- (3 , 4-dichlorobenzoyl) -cyclopropane-1-N-phenyl -carboxamide , 2- (3 , 4 -dichlorobenzoyl ) -cyclopropane-1-hydroxamic acid; 2 - (3 , 4-dichlorobenzoyl) -cyclopropane-1-N-phenylsulfonyl- carboxamide ; 2- (3 , 4-dichlorobenzoyl) -cyclobutane-1-carboxylic acid; and, if the case, the C^-Cg , preferably C1-C4, alkyl esters thereof; either as single E- or Z- isomer and/or as single optical isomer or as a mixture thereof and, when appropriate, the pharmaceutically acceptable salts thereof. A further object of the present invention is also to provide a 2 -substituted benzoyl-cycloalkyl-1-carboxylic acid compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use as an active therapeutic substance, in particular as kynurenine-3 -hydroxylase enzyme inhibitor.
Object of the present invention is also the use of a compound of formula (I) , as defined above, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as kynurenine-3 -hydroxylase enzyme inhibitor.
The present invention also provides a method of treating a mammal, including human, in need of a kynurenine-3 -hydroxylase
inhibitor, such method comprising adminstering thereto a therapeutically effective amount of a compound of formula (I), as defined above, or a pharmaceutically acceptable salt thereof .
The compounds of the invention and the salts thereof can be obtained, for instance, by a process comprising: a) reacting a compound of formula (II)
wherein R and Rx are as defined above, with a compound of formula (III)
wherein R2 is as defined above and R3 is C^Cg alkoxy, to obtain a compound of formula (I) wherein R3 is CAC6 alkoxy and E is an unsubstituted Cx-alkylene (-CH2-) group; or b) reacting a compound of formula (IV)
wherein E is as defined above; R12 is C-L-Cg alkyl and X is halogen; with a compound of formula (V)
wherein R and R± are as defined above, thus obtaining a compound of formula (I) wherein R3 is C-L-Cg alkoxy and R2 is hydrogen; or c) deacylating a compound of formula (VI)
wherein R and Rx are as defined above and BOC means tert- butoxycarbonyl , thus obtaining a compound of formula (I) wherein R2 is -NHC0R9 in which R9 is tert-butoxy and R3 is methoxy and E is an unsubstituted C alkylene chain; and, if desired converting a compound of formula (I) into another compound of formula (I), and/or, if desired, converting a compound of formula (I) into a salt thereof, and/or, if desired, converting a salt of a compound of formula (I) into a free compound of formula (I), and/or, if desired, separating a mixture of isomers of a compound of formula (I; into the single isomers. The above process-variants a) , b) and c) are analogy processes which can be carried out according to well know methods in the art.
The reaction of a compound of formula (II) with a compound of formula (III) can be carried out, for example, in a suitable solvent such as, e. g. diethyl ether, in the presence of a suitable metal complex, e.g palladium (II) diacetate, at a temperature ranging from about -78°C to room temperature, for a time ranging from about 1 hours to about 24 hours. In a compound of formula (IV) the halogen atom X is preferably chlorine or bromine . The reaction of a compound of formula (IV) with a compound of
formula (V) can be carried out according to known methods; for example, following the procedure reported in: Sommerville L.F.,
Organic Synthesis, Coll. Vol. 2, 81, (1943); Child R.G.,
Arzneim. -Forsch. /Drug Res., 30, 695-702, (1980); Quallich G.J., J. Org. Chem., 55, 4971-4973 (1990); Thyes M. , J. Med . Chem.,
26, 800-807 (1983); Hester J.B., J. Med. Chem., 34, 308-315
(1991); and De Saaqui-Sannes, Pharm. Acta Helv., 66, 7, 189-192
(1991) .
For example, this reaction can be performed in the presence of a suitable Lewis acid catalyst, in an inert solvent such as, e.g., dichloromethane or 1 , 2-dichloroethane , or m an appropriate aromatic hydrocarbon such as, e.g., chlorobenzene , nitrobenzene or in an excess of a compound of formula (V) itself; optionally in the presence of a co- solvent, e.g. nitromethane .
A suitable Lewis acid may be, e.g. anhydrous aluminium trichloride, anhydrous zinc dichloride, typically anhydrous aluminium trichloride. Deacylation of a compound of formula (VI) can be accomplished by treatment with a suitable deacylating agent, e.g. nydrazme hydrate, in a suitable solvent, e.g. anhydrous methanol . The reaction may be carried out at a temperature ranging from about 0 to about 30°C, for a time between about 0.5 and about 24 hours . Also the optional conversion of a compound of formula (I) into another compound of formula (I) can be carried out according to known methods .
For example, hydrolysis of a compound of formula (I) wherein R3 is Cx-Cg alkoxy to obtain a compound of formula (I) wherein R3 is hydroxy can be carried out according to well known methods in the art. For instance, this reaction can be performed in an aqueous or hydroalcoholic alkali solution, for example sodium
hydroxide, at a concentration ranging between 0.01 and 12N, at a temperature ranging from -20 °C to reflux temperature or by acid hydrolysis, for instance, using an aqueous solution of hydroholic acids, typically hydrochloric acid, in a suitable solvent, e.g. acetic acid, at a temperature ranging from about 0°C to reflux temperature.
A compound of formula (I) wherein R3 is hydroxy, can be converted in another compound of formula (I) wherein R3 is C-^Cg alkoxy, phenoxy or benzyloxy, by conventional alkylating methods, e.g. by treatment with a suitable alkylating agent, preferably a iodo derivative, in the presence of a base, e.g. potassium bicarbonate, in a suitable solvent, e.g. dimethylformamide , at a temperature ranging from about 0°C to about 60 °C. A compound of formula (I) wherein R3 is hydroxy, can be converted into another compound of formula (I) , wherein R3 is -N(R7R8) by conventional methods, e.g. methods employed usually in the chemistry of peptides. In particular, a compound of formula (I) wherein R3 is a N(R7R8) wherein R~ and R3 are both hydrogen can be converted into a compound of formula (I) wherein R7 and R8 are, each independently, C^Cg alkyl, benzyl or phenyl, by alkylative procedures known in the literature. The optional salification of a compound of formula (I) as well as the conversion of a salt into the free compound and the separation of a mixture of isomers into the single isomers may be carried out by conventional methods.
As stated above, the compounds of the invention have asymmetric carbon atoms and can have E/Z isomerism. Accordingly, they can be synthesized either as a mixture of isomers and then the desired isomer is separated by conventional techniques, or synthesis can be carried out by known stereospecific processes to obtain a single isomeric compound.
A compound of formula (II) , as defined above can be obtained, for instance, by reacting a compound of formula (VII)
wherein
R and R are as defined above, with diazomethane , for example, in a suitable solvent such as, e.g. diethyl ether, at a temperature varying between -78°C and room temperature, for a time ranging between 1 and 24 hours. Compounds of formula (III) and (VII) are known compounds or can be prepared according to known procedures .
A compound of formula (IV) can be obtained by a multi-step process comprising the reaction of a compound of formula (VIII)
wherein R12 and E are as defined above, with an alkali agent to obtain a compound of formula (IX)
wherein R12 and E are as defined above.
A compound of formula (IX) can then be reacted with a halogenating agent to obtain a compound of formula (IV) as defined above.
The reaction of a compound of formula (VIII) to obtain a compound of formula (IX) can be accomplished by basic hydrolysis, i.e using an alcoholic solution of an alkali metal
hydroxide, typically a potassium hydroxide solution in suitable alkoholic medium, i.e. methanol, at a suitable temperature, e.g. between 0 and 55°C, for a suitable time, e.g. 2-24 hours. The reaction of a compound of formula (IX) to obtain a compound of formula (VI) can be accomplished in a suitable halogenating agent, i.e. oxalyl chloride or bromide or thionyl chloride, typically oxalyl chloride, in the presence or the absence of a solvent, at a suitable temperature, e.g. 0-40°C, for a suitable time, e.g. 1-6 hours.
The compounds of formula (V) and (VIII) are known compounds. A compound of formula (VI) can be obtained by a multi-step process comprising acid oxidation of a compound of formula (X)
wherein R and R1 are as defined above, to obtain a compound of formula (XI)
wherein R and Rx are as defined above.
Acid oxidation of a compound of formula (X) can be accomplished for instance by using a dimethylsulfoxide (DMSO) solution of concentrated hydrobromic acid, e.g. aqueous 48% hydrobromic acid .
The reaction may be carried out at a temperature ranging from about 25 to about 100 °C, for a time between about 2 and about 48 hours.
A compound of formula (XI) can be then converted into a compound of formula (XII)
wherein R and Rx are as defined above, by treatment with a suitable hyppuric acid derivative in the presence of a suitable acylating agent, e.g. acetic anhydride. The reaction may be carried out at a temperature ranging from about 50 to about 200°C, for a time between about 0.5 and about 24 hours. A compound of formula (XII) , if desired, can be converted into its isomer of formula (Xlla)
The conversion of a compound of formula (XII) into a compound of formula (Xlla) can be accomplished using a suitable hydrohalic acid solution, e.g. 48% aqueous hydrobromic acid saturated with anhydrous hydrogen bromide gas, at a suitable temperature, e.g. between about -20 and about 25°C, for a suitable time, e.g. 15 minutes to 24 hours. Cyclopropanation of a compound of formula (XII) or (Xlla) provides a compound of formula (XIII) and (Xllla) , respectively
wherein R and Rλ are as defined above.
The reaction can be accomplished by treatment of a compound of formula (XII) or (Xlla), respectively, with an ethereal solution of diazomethane . The reaction can be carried out at a temperature ranging from about -78 and about 25°C, for a time between about 2 and about 48 hours.
A compound of formula (XIII) or (Xllla) is then converted into a compound of formula (XIV) or (XlVa) , respectively
wherein R and Rλ are as defined above The reaction can be accomplished by treatment with dimethylaminopyridme (DMAP) m methanol The reaction may be carried out at a temperature ranging from about 0 to about 50°C, for a time between about 10 minutes and 48 hours Subsequent reaction of a compound of formula (XIV) or (XlVaj with di-t-butyl-carbonate and DMAP m a suitable solvent, e g anhydrous dichloromethane provides a compound of formula 'VI) , which can be represented by the respective two isomeric
compounds of formula (XV) and (XVa)
wherein R and Rx are as defined above.
The reaction can be carried out at a temperature ranging from about 0 to about 50°C, for a time between about 1 and 24 hours. The isomeric compounds of formula (XV) and (XVa) , for convenience, are herein represented as a compound of formula (VI) . The compounds of formula (X) and the above hyppuric acid derivatives are known compounds.
When in the compounds of the invention and the intermediate thereof groups are present which may interfere with the reaction they may be protected before the reaction takes place and then deprotected at the end of the reaction. For instance, hydroxy, amino and/or carboxy groups may be protected and then deprotected according to the common techniques known from the peptide chemistry.
The compounds of the invention are active as kynurenine-3 - hydroxylase enzyme inhibitors and therefore are useful in the prevention and/or treatment of neuropathological processes, related to a deranged production of quinolinic acid and/or 3- hydroxykynurenine due to excessive activation of neuro- transmission mediated by excitatory amino acid receptors and/or oxidative stress. Examples of such neuropathological processes
are neurodegenerative pathologies including, e.g. Huntington's chorea, Alzheimer's disease, Parkinson's disease, olivoponto cerebellar atrophy, non-Alzheimer's dementias, including the dementia like syndrome caused by Acquired Immunodeficiency Syndrome (AIDS) , multi-infarctual dementia, cerebral amyotrophic lateral sclerosis, cerebral ischemia, cerebral hypoxia, spinal and head trauma and epilepsy.
A human or animal in need of a kynurenine-3 -hydroxylase enzyme inhibitor can thus be treated by a method which comprises the administration thereto of a therapeutically effective amount of a compound of the invention or a salt thereof . The condition of the human or animal can thereby be improved .
The efficacy of the compounds of the invention in the inhibition of the enzyme kynurenine-3 -hydroxylase was evaluated e.g., in rat liver mitochondrial extract following the method reported below, according to the procedure described in "Analytical Bioche . (1992), 205, 257-262", with minor modifications . The assay for kynurenine 3 -hydroxylase is based on the enzymatic synthesis of tritiated water during the hydroxylation reaction. Radiolabeled water was quantified following selective adsorption of the isotopic substrate and its metabolite with activated charcoal. Rat liver mitochondrial extract was used as enzymatic preparation for this assay.
The assay for kynurenine 3 -hydroxylase activity was carried out at 37°C for a time o 30 min . The reaction mixture of a total volume of 30μl was constituted of 44 μg of suspended extract, 100 mM Tris/Cl' buffer pH 8.1 , 10 mM EDTA, 100 mM KCl, 0.8 mM NADPH, 0.025 mM L-Kynurenine , 0.3 μCi L- (3 , 5 -3H) Kynurenine (10
Ci/mmol) and 3 μl of different concentration of inhibitor solutions. After the incubation, the reaction was terminated by the addition of 300 μl of 7.5% (W/v) activated charcoal, vortexed and centπfuged for 7 mm.. A 75 μl aliquot of supernatant was transferred to optiplate and 200 μl of liquid scintillation added. The optiplates were vortexed and the radioactivity counted in a scintillation counter.
The obtained results, which have been reported m the following Table 1, demonstrate the efficacy of a representative compound of the invention (E) -2- (3 , 4 -dichlorobenzoyl ) -cyclopropane- 1- carboxylic acid (internal code PNU-165853) .
Table 1
The dosage level, suitable for administration to a mammal, e.g. to humans, depends on the age, weight, conditions of the patient and on the administration route, for example, the dosage adopted for oral administration, for instance for the representative compound of the invention PNU 165853, may range from about 10 to about 500 mg pro dose, from 1 to 5 times daily.
The compounds of the invention can be administered m a variety of dosage forms, e.g orally, m the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally m the form of suppositories; parenterally, e.g. mtramuscolarly, or by intravenous and/or mtrathecal and/or mtraspmal injection or infusion.
The invention includes also pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent) . The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form. For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gum, gelatin, methylcellulose , carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates , laurylsulphates ; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes. The liquid dispersions for oral administration may be e.g. syrups, emulsions and suspensions. The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol . The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspension or solutions for intramuscolar injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl
oleate, glycols, e.g. propylene glycol, and, if desidered, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, acqueous, isotonic saline solutions or they may contain as a carrier propylene glycol .
The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
The following examples illustrate but do not limit the invention .
Example 1 Preparation of 3.4-dichlorobenzoyl chloride
A suspension of 3 , 4-dichlorobenzoic acid (10 g, 52.35 mmol) in thionyl chloride (50 ml) was refluxed for 12 hours under magnetic stirring and a nitrogen atmosphere. Thionyl chloride was removed under vacuum and the solid was washed with anhydrous benzene (3 x 50 ml) and dried under reduced pressure (0.1 mm/Hg) , giving 10.9 g of 3 , 4-dichlorobenzoyl chloride (100%) .
Analogously, the following products can be prepared: 3 -chlorobenzoyl chloride; 3 -fluorobenzoyl chloride; and 3-bromobenzoyl chloride.
Example 2
Preparation of 3.4-dichlorophenyl-α-diazo-methyl ketone
A solution of 3 , 4-dichlorobenzoyl chloride (10.9 g, 52.35 mmol) in anhydrous benzene (55 ml) was added over 1 h to a magnetically stirred solution of diazomethane (370 ml containing 287.9 mmol of diazomethane) , maintained at a temperature between -10°C and -15°C, under nitrogen atmosphere.
After 3 hours at -15°C the resulting pale yellow solid was filtered under reduced pressure and washed with anhydrous ethyl ether (2 x 50 ml) . 10.9 g of 3 , 4-dichlorophenyl-α-diazo-methyl ketone were obtained (97.8%) (m.p. 94.5-95.5 °C) ; IR (CHC13;
Vmax: 2110 cm"1)
Analogously, the following products can be prepared:
3 -chlorophenyl-α-diazo-methyl ketone ; 3 -fluorophenyl-α-diazo-methyl ketone; and
3 -bromophenyl-α-diazo-methyl ketone .
Example 3
Preparation of t-butyl (E) 2 - ( 3 A-dichlorobenzoyl ) -cyclopropyl- l-carboxylate and t-butyl (Z) 2- (3.4 -dichlorobenzoyl ) - cyclopropyl -1 -carboxylate .
To a suspension containing dichloromethane (30 ml), t- butylacrylate (5.96 ml, 40.71 mmol) and Pd ( II) (OAc) 2, maintained under magnetic stirring and argon atmosphere, a solution of 3 , 4-dichlorophenyl-α-diazo-methyl ketone (2.5 g; 11.63 mmol) in dichloromethane (200 ml) was added during 8 h. After 3 h at room temperature, dichloromethane was removed under reduced pressure and the mixture was submitted to flash chromatography. Elution with light petroleum/diethyl ether 90:10 afforded t-butyl (E) -2 - (3 , 4-dichlorobenzoyl ) -cyclopropyl- 1-carboxylate (1 g; 27%) . Following elution with light
petroleum/diethyl ether 80:20 t-butyl (Z)-2-(3,4- dichlorobenzoyl) -cyclopropyl-1-carboxylate (0.4, 11%) was recovered.
XH-NMR (CDC13) [ (E) -t-butyl-2 - (3 , 4 -dichlorobenzoyl) -cyclopropyl - 1-carboxylate]: δ 1.3-1.7 (m, 11H, COOt-Bu, 3-CH2); 2.3-2.5 (m, 1H, 2-CH, J=7 Hz); 2.9-3.1 (m, 1H, 4-CH, J=7 Hz); 7.5 (d, 1H, 5'-CH, J=7.5 Hz); 7.9 (dd, 1H, 6'-CH, J0=8.5 Hz, Jm=2 Hz); 8.2 (d, 1H, 2' -CH, Jm=2 Hz) .
13C-NMR (CDC13) [(E) -t-butyl-2- (3, 4-dichlorobenzoyl) - cyclopropyl-1-carboxylate]: δ 18.02; 24.68; 25.83; 28.06; 127.14; 130.06; 130.67; 133.27; 136.27; 137.92; 174.36; 195.04.
^Η- R (CDCI3) [(Z) -t-butyl-2- (3, 4-dichlorobenzoyl) -cyclopropyl - 1-carboxylate]: δ 1.3-1.7 (m, 10H, COOt-Bu, 3-(H)CH); 1.7-1.9 (m, 1H, 3-(H)CH, J=7 Hz); 2.3-2.4 (m, 1H, 2-CH, J=7 Hz); 2.7- 2.8 (dd, 1H, 4-CH, J=8.4 Hz); 7.5 (d, 1H, 5'-CH, J=7.5 Hz); 7.8 (dd, 1H, 6'-CH, J0=8.5 Hz, Jm=2 Hz) ; 8.1 (d, 1H, 2'-CH, J„.=2 Hz) .
13C-NMR (CDCI3) [(Z) -t-butyl-2- (3, 4-dichlorobenzoyl) - cyclopropyl -1-carboxylate]: δ 12.17; 24.08; 26.09; 27.72; 81.11; 127.29; 130.26; 130.73; 133.15; 136.91; 137.52; 168.75; 192.23.
Analogously, the following products can be prepared:
(E) t-butyl-2- (3-chlorobenzoyl) -cyclopropyl- 1-carboxylate ;
(E) t-butyl-2- (3 -fluorobenzoyl ) -cyclopropyl -1-carboxylate ;
(E) t-butyl-2- (3 -bromobenzoyl ) -cyclopropyl -1-carboxylate ; (Z) t-butyl-2 - (3 -chlorobenzoyl ) -cyclopropyl -1-carboxylate ;
(Z) t-butyl-2- (3 -fluorobenzoyl) -cyclopropyl -1-carboxylate ; and
(Z) t-butyl-2- (3 -bromobenzoyl) -cyclopropyl -1-carboxylate .
Example 4
Preparation Q_f (E) -2- (3.4-dichlorobenzoyl) -cyclopropyl -1- carboxylic acid.
To a solution of t-butyl (E) -2- (3 , 4-dichlorobenzoyl) - cyclopropyl -1-carboxylate (0.297 g, 0.943 mmol) in ethyl acetate (25 ml) , maintained under magnetic stirring, 37% hydrochloric acid (5 ml) was added. After 2 h at room temperature, the mixture was diluted with water (5 ml) . The organic phase was separated, washed with brine (2 x 5 ml ) , dried over anhydrous sodium sulfate and concentrated under vacuum. The resulting mixture was then purified by means of flash chromatography using dichloromethane/methanol 0÷10% as eluent . (E) -2- (3 , 4 -dichlorobenzoyl) -cyclopropyl -1-carboxylic acid (56.8 mg; 41.3%) were obtained.
XH-NMR (CDC13) [(E) -2- (3, 4-dichlorobenzoyl) -cyclopropyl- 1- carboxylic acid]: δ 1.6-1.8 (t, 2H, 3-CH2, J=6 Hz); 2.3-2.5 (m, 1H, 2-CH, J=7 Hz); 3.1-3.2 (m, 1H, 4-CH, J=7 Hz); 7.5 (d, 1H ,
5'-CH, J=7.5 Hz); 7.9 (dd, 1H, 6'-CH, J0=8.5 Hz, Jm=2 Hz); 8.2
(d, 1H, 2' -CH, Jra=2 Hz) .
13C-NMR (CDC13) [(E) -2- (3, 4-dichlorobenzoyl) -cyclopropyl -1- carboxylic acid]: δ 18.02; 24.68; 25.83; 127.14; 130.06; 130.67; 133.27; 136.37; 137.92; 174.36; 195.04.
Analogously, the following products can be prepared: (E) -2- (3-chlorobenzoyl) -cyclopropyl -1-carboxylic acid; (E) -2 - (3 -fluorobenzoyl) -cyclopropyl -1-carboxylic acid; and (E) -2- (3 -bromobenzoyl) -cyclopropyl-1-carboxylic acid.
Example 5
Preparation Q_f (Z) -2- (3 , 4-dichlorobenzoyl) -cyclopropyl -1 - carboxylic acid.
To a solution of (Z) t-butyl-2- (3 , 4-dichlorobenzoyl) - cyclopropyl -1-carboxylate (0.06 g, 0.188 mmol) in ethyl acetate (5 ml) , maintained under magnetic stirring, 37% hydrochloric acid (1 ml) was added. After 2 h at room temperature, the mixture was diluted with water (5 ml) . The organic phase was separated, washed with brine (2 x 5 ml) , dried over anhydrous sodium sulfate and concentrated under vacuum. The resulting mixture was then purified by means of flash chromatography using dichloromethane/methanol 0÷15% as eluent . (Z) 2- (3,4- dichlorobenzoyl) -cyclopropyl -1-carboxylic acid (15 mg; 30.8%) was obtained.
XH-NMR (CDC13) [(Z) -2- (3, 4-dichlorobenzoyl) -cyclopropyl- 1- carboxylic acid]: δ 1.3-1.7 (t, 2H, 3-(H)CH, J=6 Hz); 1.7-1.9 (m, 1H, 3-(H)CH); 2.3-2.5 (m, 1H, 2-CH); 2.6-2.8 (m, 1H, 4-CH); 7.4-7.5 (d, 1H, 5'-CH); 7.6-7.8 (m, 1H, 6'-CH); 8.2 (d, 1H, 2'- CH) .
13C-NMR (CDC13) [(Z) -2- (3, 4-dichlorobenzoyl) -cyclopropyl- 1- carboxylic acid]: δ 13.96; 24.08; 26.09; 127.79; 130.30; 130.69; 133.14; 136.63; 138.30; 171.15; 194.23.
Analogously, the following products can be prepared: (Z) -2- (3 -chlorobenzoyl) -cyclopropyl- 1-carboxylic acid; (Z) -2- (3 -fluorobenzoyl) -cyclopropyl-l-carboxylic acid; (Z) -2- (3 -bromobenzoyl) -cyclopropyl- 1-carboxylic acid; and (Z) -2- (3 , 4 -difluorobenzoyl) -cyclopropyl-l-carboxylic acid.
Example 6
Preparation of (E) (1R, 2R) -2- (3 , 4-dichlorobenzoyl) -cyclopropyl - 1- (lR-α-phenylglycinoyl) -carboxamide and (E) (IS .2S) -2- (3 , 4 - dichlorobenzoyl) -cyclopropyl-1- (lR-α-phenylglycinoyl) - carboxamide .
(E) -2- (3 , 4-dichlorobenzoyl) -cyclopropyl-l-carboxylic acid (0.175 g, 0.68 mmol) was dissolved in oxalylchloride (6 ml) and left at room temperature for 2 h, under magnetic stirring and argon atmosphere. Oxalylchloride was removed by rotary evaporation and the corresponding 2- (3 , 4-dichlorobenzoyl ) - cyclopropyl-l-carboxylic acid chloride, dissolved in anhydrous dioxane (1.5 ml), was added to a dioxane (3.5 ml) solution containing R- ( - ) -phenylglycinol (0.093 g, 0.68 mmol) and triethylamine (0.1 ml, 0.7 mmol), maintained under magnetic stirring and argon atmosphere at 10°C. After 1 h at 10°C the reaction mixture was treated with 37% hydrochloric acid (1 ml) and ethyl acetate (10 ml) . The organic phase was separated, washed with water (3 x 10 ml) , with brine (1 x 10 ml) , dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was submitted to medium pressure chromatography on a silica gel Lobar column (60-43 μm) using light petroleum/ethyl acetate 30:70 as eluent and two amides were separated. According to the literature , the first amide eluted, ([ ]D 20 = -102.6, c = 0.5 CHC13) , can be assigned as (E, - (lR,2R)-2- (3, 4 -dichlorobenzoyl) -cyclopropyl-1-) lR-α- phenylglycinoyl) -carboxamide and the second one, ([o]D = +56, c = 1 CHC13) , as (E) - (IS, 2S) -2- (3, 4-dichlorobenzoyl) -cyclopropyi- 1- ) lR-α-phenylglycinoyl) -carboxamide (86%) .
' (a) G Helmchen, G Nill, D. Floc erzi, W Schuhle, M.S.K. Youssef, Angew Chem Int Ed Engl , 18, 1979, 62-63 (b) G Helmchen, G Nill, D Flockerzi, M.S K Youssef, wgew Chem Int Ed Engl , 18, 1979, 63-65 (c) G Helmchen. G. Nύ\„ Angew Chem Int Ed Engl , 18, 1979, 65-66
XH- MR (CDCI3) [(E) - (1R,2R) -2- (3 , 4 -dichlorobenzoyl ) -cyclopropyl - 1- (lR-α-phenylglycinoyl) -carboxamide]: δ 1.4-1.5 (t, 2H, 3- (H)CH); 1.5-1.6 (m, 1H, 3-(H)CH); 2.3-2.5 (m, 1H, 2-CH); 2.9- 3.2 (m, 1H, 4-CH and OH); ); 3.8-3.9 (d, 1H, α-CH20H) ) ; 5.0-5.1 (m, 1H, -CH) ; 6.9-7.0 (bd, 1H, NH) ; 7.2-7.4 (m, 5H, a-C6H5) ; 7.2-7.4 (m, 1H, 5'-CH, J= 7.5 Hz); 7.9 (dd, 1H, 6'-CH, Jσ=8.5 Hz, Jm=2 Hz); 8.2 (d, 1H, 2'-CH, Jm=2 Hz) .
13C-NMR (CDCI3) [(E) - (1R,2R) -2- (3, 4-dichlorobenzoyl) - cyclopropyl-1- (lR-α-phenylglycinoyl) carboxamide] : δ 18.07; 25.54; 26.84; 29.64; 56.21; 66.29; 126.67; 127.31; 127.96; 130.25; 130.78; 133.46; 136.52; 138.07; 138.69; 170.72; 195.97.
^-NMR (CDCI3) [(E) - (IS, 2S) -2- (3, 4-dichlorobenzoyl) -cyclopropyl- 1- (lR-α-phenylglycinoyl) -carboxamide]: δ 1.4-1.5 (m, 1H, 3- (H)CH); 1.5-1.6 (m, 1H, 3-(H)CH); 2.35-2.45 (m, 1H, 2-CH); 2.9- 3.1 (m, 1H, 4-CH and OH); 3.8-3.9 (d, 1H, α-CH20H) ) ; 4.9-5.0 (m, 1H, α-CH); 6.9-7.0 (bd, 1H, NH) ; 7.1-7.3 (m, 5H, a-C6H5); 7.4 (d, 1H, 5'-CH, J= 7.5 Hz); 7.6-7.7 (dd, 1H, 6'-CH, J0=8.5 Hz, Jm=2 Hz); 7.9 (d, 1H, 2'-CH, Jm=2 Hz).
13C-NMR (CDCI3) [(E) - (IS, 2S) -2- (3, 4-dichlorobenzoyl) - cyclopropyl-1- (lR-α-phenylglycinoyl) carboxamide] : δ 18.04; 25.44; 26.87; 29.64; 56.22; 66.29; 126.70; 127.31; 127.96; 128.88; 130.25; 130.74; 133.43; 136.49; 138.03; 138.76; 170.66; 195.92.
Example 7
Preparation of (E) (1R, 2R) -2-dichlorobenzoyl) -cyclopropyl- 1- carboxylic acid.
To a solution of (E) (1R, 2R) -2- (3 , 4-dichlorobenzoyl) -
cyclopropyl-1- (lR-α-phenylglycinoyl) -carboxamide (50 mg, 0.123 mmol) in dioxane (3.5 ml), maintained under magnetic stirring, 37% hydrochloric acid was added (1.5 ml) and the mixture was left at 50°C for 7 h. After cooling, the reaction mixture was diluted with ethyl acetate (40 ml) . the organic phase was washed with water (6 x 3 ml) , brine (1 x 4 ml ) , dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was submitted to flash chromatography using dichloromethane/methanol O÷IO as eluent . (E) (1R, 2R) -2- (3 , 4 - dichlorobenzoyl) -cyclopropyl-l-carboxylic acid, ([oc]D = -86, c = 0.36, CHC13) was yielded (20 mg, 75%) .
^- MR (CDC13) [(E) (1R, 2R) -2- (3 , 4-dichlorobenzoyl) -cyclopropyl- l-carboxylic acid]: δ 1.5-1.7 (t, 2H, 3-CH2, J=6 Hz) ; 2.3-2.5 (m, 1H, 2-CH); 3.0-3.2 (m, 1H, 4-CH, J=7 Hz); 7.4-7.5 (d, 1H, 5'-CH, J=7.5 Hz); 7.7-7.9 (dd, 1H, 6'-CH, J0=8.5 Hz) ; 7.9-8.1 (s, 1H, 2' -CH) .
13C-NMR (CDC13) [(E) (1R,2R) -2- (3, 4-dichlorobenzoyl) - cyclopropyl - 1-carboxylic acid]: δ 18.62; 25.01; 26.22; 127.21; 130.16; 130.82; 133.52; 136.25; 138.28; 178.11; 194.59.
Example 8
Preparation of (E) (IS , 2S) -2- (3.4 -dichlorobenzoyl ) -cyclopropyl - 1-carboxylic acid.
To a solution of (E) (IS, 2S) -2- (3 , 4-dichlorobenzoyl ) - cyclopropyl-1- (lR-α-phenylglycinoyl ) -carboxamide (50 mg, 0.123 mmol) in dioxane (3.5 ml), maintained under magnetic stirring, 37% hydrochloric acid was added (1.5 ml) and the mixture was left at 50°C for 7 h. After cooling, the reaction mixture was diluted with ethyl acetate (40 ml) . the organic phase was
washed with water (6 x 3 ml) , brine (1 x 4 ml) , dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was submitted to flash chromatography using dichloromethane/methanol O÷IO as eluent . (E) - (1R, 2R) -2- (3 , 4- dichlorobenzoyl) -cyclopropyl-l-carboxylic acid, ( ([α]D = +77, c = 0.65, CHC13) was yielded (13 mg, 49%).
^Η-NMR (CDC13) [(E) (IS, 2S) -2- (3, 4-dichlorobenzoyl) -cyclopropyl- l-carboxylic acid]: δ 1.6-1.8 (t, 2H, 3-CH2, J=7 Hz); 2.3-2.5 (m, 1H, 2-CH, J=7 Hz); 3.1-3.2 (m, 1H, 4-CH, J=7 Hz); 7.5 (d, 1H, 5'-CH, J=7.5 Hz); 7.8 (dd, 1H, 6'-CH, J0=7.5 Hz, Jm=l .5 Hz); 8.1 (s, 1H, 2 ' -CR , Jm=1.5 Hz).
13C-NMR (CDCI3) [(E) (IS, 2S) -2- (3, 4-dichlorobenzoyl) -cyclopropyl - 1-carboxylic acid]: δ 18.48; 24.68; 26.23; 127.25; 130.24; 130.86; 133.57; 136.38; 138.25; 177.61; 194.45.
Example 9
Preparation of (E) -l-methoxycarbonyl-cyclopropane-2 -carboxylic acid,
A solution of potassium hydroxide (0.354 g, 6.32 mmol) in dry methanol (4 ml) was dropped in one hour to a solution of
(E) 1 , 2-cyclopropandicarboxylate dimethyl ester (1 g, 6.32 mmol) in dry methanol (4 ml) , maintained under magnetic stirring at room temperature. The resulting solution was heated to 55°C during 12 hours and then was poured into water (10 ml) . After acidification with 10% hydrochloric acid , the aqueous phase was extracted with ethyl acetate (10 x 10 ml ) . The organic extracts were washed with brine (1 x 10 ml) , dried over anhydrous sodium sulfate and concentrated under vacuum to yield an oil that was purified by flash-chromatography . Elution with
dichloromethane/methanol (95:5) afforded the pure title compound (0.556 g; 61%).
XH-NMR (CDC13) ; δ: 1.5 (t, 2H, 2-CH2, J=8 Hz); 2.1-2.3 (m, 2H, 1-CH and 3-CH); 3.7 (s, 3H, COOCH3); 10.35 (bs, 1H, COOH) . 13C-NMR (CDCI3) ; δ: 14.94; 21.71; 22.24; 51.88; 171.74; 176.60.
Analogously the following compounds were prepared: (E) -l-methoxycarbonyl-cyclobutane-2-carboxylic acid, (E) -l-methoxycarbonyl-cyclopentane-2-carboxylic acid, (E) -1 -methoxycarbonyl-cyclohexane- 2 -carboxylic acid,
(E) - 1 -methoxycarbonyl -3 -methylene-cyclopropane- 2 -carboxylic acid,
(E) -1 -methoxycarbonyl -3 -methyl-cyclopropane-1-carboxylic acid, (E) -1 -methoxycarbonyl -3 , 3 -dimethyl -cyclopropane-1-carboxylic acid, and
(E) -1 -methoxycarbonyl -3 , 3 -difluoro- cyclopropane -1-carboxylic acid.
Example 10 Preparation of (E) -1 -methoxycarbonyl -cyclopropane-2 -carboxylic acid chloride.
A solution of (E) -1 -methoxycarbonyl -cyclopropane-2 -carboxylic acid (0.556 g, 3.857 mmol) in oxalylchloride (20 ml) was stirred under an argon atmosphere at room temperature for 3 hours, then the solution was concentrated under vacuum for 2 hours and the oily residue containing the titled compound was used in the next step without further purification.
Analogously, the following products were prepared:
(E) - l-methoxycarbonyl-cyclobutane-2-carboxylic acid chloride;
(E) -l-methoxycarbonyl-cyclopentane-2-carboxylic acid chloride; (E) -l-methoxycarbonyl-cyclohexane-2-carboxylic acid chloride; (E) - 1 -methoxycarbonyl -3 -methylene-cyclopropane-2 -carboxylic acid chloride; (E) -l-methoxycarbonyl-3-methyl-cyclopropane-2-carboxylic acid chloride;
(E) -1 -methoxycarbonyl -3 , 3 -dimethyl -cyclopropane-2 -carboxylic acid chloride and
(E) -1 -methoxycarbonyl -3 , 3 -difluoro-cyclopropane-2 -carboxylic acid chloride.
Example 11
Preparation of (E) methyl 2- (3.4-dichlorobenzoyl) -cyclopropyl -
1-carboxylate. To a magnetically stirred solution of (E) -1 -methoxycarbonyl - cyclopropane- 2 -carboxylic acid chloride (0.627 g, 3.857 mmol) in 1, 2-dichlorobenzene (10 ml), AlCl3 (1.542 g, 11.57 mmol) was added portionwise under an argon atmpsphere at 0°C. The resulting solution was stirred 10 minutes at 0°C then warmed to 55°C for 2 hours. The reaction mixture was quenched by addition of ice-water (10 ml) and 10% hydrochloric acid (10 ml) . the mixture so obtained was extracted with ethyl acetate (4 x 25 ml) ; the combined organic phases were washed with brine (1 x 10 ml), dried over an. sodium sulfate, concentrated under vacuum. The oily residue was purified by flash-chromatography : elutionwith light petroleum-ethyl acetate 100:0 to 85:15 thus affording the titled compound as an oil (0.610 mg, 58%) .
XH-NMR (CDC13) : δ: 1.6 (dd, 2H, 2-CH2, J=6.9 Hz); 2.35-2.45 (m, 1-CH) ; 3.1-3.2 (m, 1H, 3-CH); 3.7 (s, 3H, COOCH3 ) ; 7.55 (d, 1H, 6'-CH, JD=8 Hz); 7.85 (dd, 1H, 5'-CH, J0=8Hz, Jm=2 Hz); 8.05 (dd, 1H, 2' -CH, J =2 Hz) .
13C-NMR (CDCI3) : δ : 17.78; 24.39; 25.49; 51.86, 127.00; 129.87, 130.44; 133.04; 136.25; 137.56; 171.88; 194.23.
Analogously the following products were prepared:
(E) -methyl 2- (3 , 4-dichlorobenzoyl) -cyclobutyl- 1-carboxylate ;
(E) -methyl 2- (3 , 4-dichlorobenzoyl) -cyclopentyl-1-carboxylate ;
(E) -methyl 2- (3 , 4-dichlorobenzoyl) -cyclohexyl -1-carboxylate ;
(E) -methyl -2- (3 , 4-dichlorobenzoyl) -3-methylene-cyclopropane-l - carboxylate;
(E) -methyl -2- (3 , 4 -dichlorobenzoyl) -3 -methyl-cyclopropane-1 - carboxylate ;
(E) -methyl -2- (3 , 4-dichlorobenzoyl) -3 , 3-dimethyl-cyclopropane-l - carboxylate and (E) -methyl-2- (3 , 4-dichlorobenzoyl) -3,3 -difluoro-cyclopropane- 1- carboxylate .
Example 12
Preparation of (E) 2- (3 , 4-dichlorobenzoyl ) -cyclopropane- 1- carboxylic acid
To a magnetically stirred solution of (E) -methyl 2- (3,4- dichlorobenzoyl) -cyclopropyl- 1-carboxylate (70 mg, 0.244 mmol) in dry dioxane (3.5 ml), a solution of sodium hydroxide (19.5 mg, 0.488 mmol) in water (1.5 ml) was added. After 2 hours at room temperature, the mixture was diluted with water (10 ml and extracted with dichloromethane (2 x 2 ml ) . The acqueous layer was acidified with 10% hydrochloric acid, then extracted with ethyl acetate (4 x 5 ml) , the combined organic phases were washed with brine (1 x 5 ml) , dried over an. sodium sulfate and concentrated under vacuum to obtain the titled compound (50 mg,
79%) as a white solid.
XH-NMR (Acetone-d6) : δ: 1.6 (m, 2H, 2-CH2) ; 2.35-2.45 (m, 1-CH) ; 3.25 (m, 1H, 3-CH); 7.75 (d, 1H, 6'-CH, JQ=8 Hz); 8.05 (dd, 1H, 5'-CH, J0=8 Hz, Jm=2 Hz); 8.2 (d, 1H, 2'-CH, Jm=2 Hz).
13C-NMR (CDC13) : δ : 18.16; 25.05; 26.38; 128.79; 130.91, 131.87; 133.55; 137.91; 173.01; 195.48.
Analogously the following products were prepared: (E) -2- (3 , 4-dichlorobenzoyl) -cyclobutyl-1-carboxylic acid;
(E) -2- (3 , 4-dichlorobenzoyl) -cyclopentyl-1-carboxylic acid;
(E) -2- (3 , 4-dichlorobenzoyl) -cyclohexyl- 1-carboxylic acid.
2- (3 , 4-dichlorobenzoyl) -3-methylene-cyclopropane-l-carboxylic acid; 2- (3 , 4-dichlorobenzoyl) -3 -methyl -cyclopropane- 1-carboxylic acid;
2- (3 , 4-dichlorobenzoyl) -3 , 3 -dimethyl-cyclopropane -1-carboxylic acid; and
2- (3,4 -dichlorobenzoyl) -3 , 3 -difluoro-cyclopropane- 1-carboxylic acid.
Example 13
Preparation of 3 , 4-dichlorophenylglyoxal
To a stirred solution of 3 , 4-dichloroacetophenone (1 mmol) in DMSO (3 ml) , 48% aqueous hydrobromic acid (3 mmol) was added slowly. The solution was stirred in an open flask at 55°C. When the starting material was consumed (24 hours) , the solution was poured into ice. The crude product was extracted into Et=Ac, the solution was washed with water, dried over anhydrous sodium sulfate and concentrated under vacuum. The titled arylglyoxal was recovered in an essentially pure form.
Analogously, the following products can be prepared: 3 -chlorophenylglyoxal ; 3 -fluorophenylglyoxal ; 3-bromophenylglyoxal ; and 3 , 4 -difluorophenylglyoxal .
Example 14
Preparation of (Z) -2-Phenyl-4 - (3.4-dichlorobenzoylmethylene) - oxazol-5-one .
A mixture of 3 , 4-dιchlorophenylglyoxal (1 mmol), powdered dry hyppuric acid (1 mmol), powdered freshly fused sodium acetate
(1 mmol) and high-grade acetic anhydride, is heated on an electric hot plate with constant shaking m an apparatus fitted with a calcium chloride tube. As soon as the material has liquefied completely, the flask is transferred to a steam bath and heated for two hours, during this time a part of the product separates as crystals. At the end of the heating, ethyl alcohol is added slowly into the flask, while maintaining the temperature below 30°C. After allowing the reaction mixture to stand overnight, the crystalline product is filtered with suction, . The pure azlactone is collected as a white solid.
Analogously the following products were prepared: (Z) -2-Phenyl-4- (3 -chlorobenzoyl ethylene) -oxazol -5-one ; (Z) -2-Phenyl-4- (3 -fluorobenzoylmethylene) -oxazol -5-one ; (Z) -2-Phenyl-4- (3 -bromobenzoylmethylene) -oxazol-5-one ; and (Z) -2-Phenyl-4- (3 , 4-difluorobenzoylmethylene) -oxazol-5-one .
Example 15
Preparation of (Z) -2- (3 , 4-dichlorobenzoyl) -5-phenyl-6-oxo-4- azaspiro-[2 , 4]-hept-4-en-7-one .
A solution of (Z) -2-Phenyl-4- (3 , 4-dichlorobenzoylmethylene) - oxazol -5 -one (1 mmol) in anhydrous methylene was treated with an ethereal solution of diazomethane (10 mmol, under magnetic stirring. The mixture was allowed to stand at room temperature overnight, treated with anhydrous calcium chloride to destroy exces diazomethane, filtered and concentrated under vacuum. The resultant oil was purified by flash-chromatography . Elution with light petroleum-ethyl acetate afforded the pure titled derivative .
Analogously the following derivatives were prepared: (Z) -2- (3 , 4 -difluorobenzoyl) -5-phenyl-6-oxo-4-azaspiro-[2 , 4]- hept-4 -en- 7 -one ;
(Z) -2- (3-chlorobenzoyl) -5-phenyl -6 -oxo-4-azaspiro-[2 , 4]-hept-4- en-7-one ;
(Z) -2- (3 -fluorobenzoyl ) -5-phenyl -6 -oxo-4 -azaspiro-[2 , 4]-hept-4 - en- 7 -one; and
(Z) -2- (3 -bromobenzoyl) -5-phenyl -6 -oxo-4 -azaspiro-[2 , 4]-hept-4- en-7-one .
Example 16 Preparation of (Z) -Methyl 2- (3 , 4 -dichlorobenzoyl) -1- benzamidocyclopropane- 1-carboxylate .
DMAP (1 mmol) was added to a suspension of (Z)-2-(3,4- dichlorobenzoyl) -5-phenyl-6-oxo-4-azaspiro-[2 , 4]-hept-4 -en- 7- one ( 1 mmol) in absolute methanol and the resulting mixture was magnetically stirred at room temperature for 35 minutes. Methanol was removed under vacuum, the crude product was
treated with a mixture 1:1 of dichloromethane and 5% aq. citric acid, the organic phase was collected and the aqueous phase was extracted with an additional amount of dichloromethane. The organic extracts were combined, dried over an. sodium sulfate and concentrated to give the titled compund.
Analogously the following derivatives were prepared:
(Z) -Methyl 2- (3 , 4 -difluorobenzoyl) -1-benzamidocyclopropane-l- carboxylate ; (Z) -Methyl 2- (3-chlorobenzoyl) -1-benzamidocyclopropane-l- carboxylate ;
(Z) -Methyl 2- (3 -fluorobenzoyl) -1-benzamidocyclopropane-l- carboxylate; and
(Z) -Methyl 2- (3 -bromobenzoyl) -1-benzamidocyclopropane-l- carboxylate .
Example 17
Preparation of (Z) -Methyl 2- (3 , 4-dichlorobenzoyl) -1- (N-benzoyl-
N-t -butoxycarbonylamino) -cyclopropane- 1-carboxylate . Di- t-butyl dicarbonate (2 mmol) and DMAP (1 mmol) were added to a suspension of (Z) -Methyl 2- (3 , 4-dichlorobenzoyl) -1- benzamidocyclopropane- 1-carboxylate (1 mmol) in anhydrous dichloromethane and the resulting mixture was kept under magnetic stirring in a nitrogen atmosphere at room temperature for two hours. After evaporation of the solvent, the crude reaction product was dissolved in dichloromethane, washed with 5% citric acid, brine and dried over anhydrous sodium sulfate. Evaporation of the solvent yielded the pure titled compound.
Analogously the following derivatives were prepared:
(Z) -Methyl 2- (3 , 4-dichlorobenzoyl) -1- (N-benzoyl-N-t-
butoxycarbonylamino) -cyclopropane- 1-carboxylate ;
(Z) -Methyl 2- (3 , 4-difluorobenzoyl) -1- (N-benzoyl-N-t- butoxycarbonylamino) -cyclopropane- 1-carboxylate ;
(Z) -Methyl 2- (3-chlorobenzoyl) -1- (N-benzoyl-N-t- butoxycarbonylamino) -eyelopropane- 1 -carboxylate ;
(Z) -Methyl 2- (3 -fluorobenzoyl) -1- (N-benzoyl-N-t- butoxycarbonylamino) -cyclopropane-1-carboxylate ; and
(Z) -Methyl 2- (3 -bromobenzoyl) -1- (N-benzoyl-N-t- butoxycarbonylamino) -cyclopropane-1-carboxylate .
Example 18
Preparation of (Z) -Methyl 2- ( .4 -dichlorobenzoyl) -1-t- butoxycarbonylamino-cyclopropane- 1-carboxylate .
Hydrazine hydrate (10 mmol) was added to a magnetically stirred suspension of (Z) -Methyl 2- (3 , 4 -dichlorobenzoyl) -1- (N-benzoyl - N-t-butoxycarbonylamino) -cyclopropane- 1-carboxylate in anhydrous methanol at room temperature. Stirring was continued for one hour after which the solvent was evaporated, while maintaining the temperature of the water bath below 30°C. The residue was then flash-chromatographed (eluent: chloroform- methanol ; 9:1) to afford the titled compound.
Analogously the following derivatives were prepared:
(Z) -Methyl 2- (3,4 -difluorobenzoyl) -1-t-butoxycarbonylamino- cyclopropane-1-carboxylate ;
(Z) -Methyl 2- (3-chlorobenzoyl) -1- t-butoxycarbonylamino- cyclopropane-1 -carboxylate ;
(Z) -Methyl 2- (3 -fluorobenzoyl) -1- t-butoxycarbonylamino- cyclopropane- 1 -carboxylate ; and (Z) -Methyl 2- (3 -bromobenzoyl) -1-t-butoxycarbonylamino- cyclopropane-1-carboxylate .
Example 19
Preparation of (Z) -Methyl 2 - (3.4-dichlorobenzoyl) -1-amino- cyclopropane- 1-carboxylate 12 N Hydrochloric acid was added to a solution of (Z) -Methyl 2- (3 , 4-dichlorobenzoyl) -1-t-butoxycarbonylamino-cyclopropane-l- carboxylate in ethyl acetate and the resulting mixture was magnetically stirred at room temperature for 30 minutes. The reaction mixture was then neutralised with saturated sodium hydrogen carbonate, the organic phase separated and the aqueous layer was extracted with ethyl acetate. The combined organic phase were washed with brine and dried over anhydrous sodium sulfate. Evaporation of the solvent gave the titled methyl ester .
Analogously the following derivatives were prepared: (Z) -Methyl 2- (3-chlorobenzoyl) -1-amino-cyclopropane-l- carboxylate ; (Z) -Methyl 2- (3 -bromobenzoyl ) -1-amino-cyclopropane-l- carboxylate;
(Z) -Methyl 2- (3 -fluorobenzoyl) -1-amino-cyclopropane-l- carboxylate; and
(Z) -Methyl 2- (3 , 4-difluorobenzoyl) -1-amino-cyclopropane- 1-carboxylate .
Example 20
Preparation of (Z) -2- (3 , 4 -dichlorobenzoyl) -1-amino- cyclopropane- 1-carboxylic acid.
I N Lithium hydroxide monohyrate was added to a solution of
(Z) -Methyl 2- (3 , 4 -dichlorobenzoyl ) -1 -amino-cyclopropane-1-
carboxylate in dioxane and the resulting mixture was kept under magnetic stirring at room temperature overnight. The reaction mixture was then evaporated to dryness, the residue diluted with water and neutralised with 1 N hydrochloric" acid. Ion exchange chromatography on Dowex 50x2 200 and elution with 10% pyridine yielded the titled compound.
Analogously the following derivatived were prepared:
(Z) -2- (3 , 4 -difluorobenzoyl) -1-amino-cyclopropane-l-carboxylic acid;
(Z) -2- (3-chlorobenzoyl) -1-amino-cyclopropane-l-carboxylic acid;
(Z) -2- (3 -fluorobenzoyl) -1-amino-cyclopropane-l-carboxylic acid; and
(Z) -2- (3 -bromobenzoyl) -1-amino-cyclopropane-l-carboxylic acid.
Analogously starting from the alkyl esters described in all the preceding examples the respective free 1-carboxylic acids can be obtained.
Example 21
Preparation of (E) -2-Phenyl-4- (3 , 4-dichlorobenzoylmethylene) - oxazol-5-one .
A suspension of (Z) -2-Phenyl-4- (3 , 4-dichlorobenzoylmethylene) - oxazol-5-one in 48% hydrobromic acid, kept at 0°C and maintained under magnetic stirring, was saturated with anhydrous hydrogen bromide gas for 30 minutes and left in a refrigerator overnight. The product was poured into crushed ice and the solid (E) -azlactone was filtered, washed with ice-water and dried over phosphorous pentoxide .
Analogously the following derivatives were prepared:
(E) -2-Phenyl-4- (3-chlorobenzoylmethylene) -oxazol -5-one ;
(E) -2-Phenyl-4- (3 -fluorobenzoylmethylene) -oxazol-5-one;
(E) -2-Phenyl-4- (3-bromobenzoylmethylene) -oxazol-5-one; and
(E) -2 -Phenyl-4- (3 , 4 -difluorobenzoylmethylene) -oxazol -5-one .
Example 22
Preparation Of (E) -2- (3.4-dichlorobenzoyl) -5-phenyl-6-oxo-4- azaspiro-[2.4]-hept-4-en-7-one .
A solution of (E) -2-Phenyl-4- (3 , 4-dichlorobenzoylmethylene) - oxazol -5 -one (1 mmol) in anhydrous dichloromethane was treated with an ethereal solution of diazomethane (10 mmol) under magnetic stirring. The mixture was allowed to stand at room temperature overnight, treated with anhydrous calcium chloride to destroy excess diazomethane, filtered and concentrated under vacuum, the resultant oil was purifird by flash-chromatography . elution with light petroleum-ethyl acetate afforded the pure titled derivative.
Analogously the following derivatives were prepared: (E) -2- (3 , 4 -difluorobenzoyl) -5 -phenyl-6 -oxo-4 -azaspiro-[2 , 4]- hept-4 -en- 7 -one ;
(E) -2- (3-chlorobenzoyl) -5-phenyl-6-oxo-4-azaspiro-[2 , 4]-hept-4 - en-7-one;
(E) -2- ( 3 -fluorobenzoyl) -5-phenyl-6-oxo-4-azaspiro-[2 , 4]-hept-4 - en-7-one; and
(E) -2- (3 -bromobenzoyl) -5-phenyl-6-oxo-4-azaspiro-[2 , 4]-hept-4 - en-7-one .
Example 23
Preparation of (E) -Methyl 2- (3 , 4-dichlorobenzoyl ) -1- benzamidocyclopropane-1-carboxylate.
DMAP (1 mmol) was added to a suspension of (E)-2-(3,4- dichlorobenzoyl) -5-phenyl-6-oxo-4-azaspiro-[2 , 4]-hept-4-en-7- one(l mmol) in absolute methanol and the resulting mixture was magnetically stirred at room temperature for 30 minutes. Methanol was removed under vacuum, the crude product was treated with a mixture 1:1 of dichloromethane and 5% aq . citric acid. The organic phase was collected and the aqueous phase was extracted with an additional amount of dichloromethane . The organic extracts were combined, dried over an. sodium sulfate and concentrated to give the titled compound.
Analogously the following derivatives were prepared:
(E) -Methyl 2- (3 , 4 -difluorobenzoyl) -1-benzamidocyclopropane-l- carboxylate;
(E) -Methyl 2- (3-chlorobenzoyl) -1-benzamidocyclopropane-l- carboxylate; (E) -Methyl 2- (3- fluorobenzoyl) -1 -benzamidocyclopropane-1- carboxylate; and
(E) -Methyl 2- (3 -bromobenzoyl) -1-benzamidocyclopropane-l- carboxylate .
Example 24
Preparation of (E) -Methyl 2- (3 , 4-dichlorobenzoyl) -1- (N-benzoyl- N-t-butoxycarbonylamino) -cyclopropane-1-carboxylate . Di-t-butyl dicarbonate (10 mmol) and DMAP (0.2 mmol) were added to a suspension of (E) -Methyl 2- (3 , 4 -dichlorobenzoyl) - 1- benzamidocyclopropane- 1-carboxylate (1 mmol) in anhydrous tetrahydrofuran and the resulting mixture was kept under magnetic stirring in a nitrogen atmosphere at room temperature
for 22 hours. After evaporation of the solvent, the crude reaction product was dissolved in dichloromethane, washed with 5% citric acid, brine and dried over anhydrous sodium sulfate. Evaporation of the solvent yielded a residue which was submitted to flash chromatography: elution with light petroleum ether-ethyl acetate afforded the pure titled compound.
Analogously the following derivatives were prepared: (E) -Methyl 2- (3 , 4 -dichlorobenzoyl) -1- (N-benzoyl-N- t- butoxycarbonylamino) -cyclopropane-1-carboxylate ;
(E) -Methyl 2- (3 , 4-difluorobenzoyl ) -1- (N-benzoyl -N-t- butoxycarbonylamino) -cyclopropane - 1 -carboxylate ; (E) -Methyl 2- (3-chlorobenzoyl) -1- (N-benzoyl-N-t- butoxycarbonylamino) -cyclopropane- 1-carboxylate ; (Z) -Methyl 2- (3 -fluorobenzoyl ) -1- (N-benzoyl-N- t- butoxycarbonylamino) -cyclopropane -1 -carboxylate ; and (E) -Methyl 2- (3 -bromobenzoyl) -1- (N-benzoyl -N-t- butoxycarbonylamino) -cyclopropane- 1-carboxylate .
Example 25
Preparation of (E) -Methyl 2- (3 , 4 -dichlorobenzoyl) -1-t- butoxycarbonylamino-cyclopropane- 1-carboxylate .
Hydrazine hydrate (10 mmol) was added to a magnetically stirred suspension of (E) -Methyl 2- (3 , 4 -dichlorobenzoyl ) -1- (N-benzoyl - N-t-butoxycarbonylamino) -cyclopropane-1-carboxylate in anhydrous methanol at room temperature. Stirring was continued for 15 minutes after which the solvent was evaporated on a rotary evaporator while maintaining the temperature of the water bath below 30°C. The residue was then flash- chromatographed (eluent: chloroform-methanol ; 9:1) to afford the titled compound.
Analogously the following derivatives were prepared: (E) -Methyl 2- (3 , 4 -difluorobenzoyl) -1-t-butoxycarbonylamino- cyclopropane- 1-carboxylate ; (E) -Methyl 2- (3 -chlorobenzoyl) -1-t-butoxycarbonylamino- cyclopropane- 1-carboxylate ;
(E) -Methyl 2- (3 -fluorobenzoyl) -1-t-butoxycarbonylamino- cyclopropane-1-carboxylate ; and
(E) -Methyl 2- (3 -bromobenzoyl) -1-t-butoxycarbonylamino- cyclopropane- 1 -carboxylate .
Example 26
Preparation of (E) -Methyl 2- (3 , 4 -dichlorobenzoyl) -l-amino- cyclopropane- 1 -carboxylate 12 N Hydrochloric acid was added to a solution of (E) -Methyl 2-
(3 , 4-dichlorobenzoyl ) -1-t-butoxycarbonylamino-cyclopropane-l- carboxylate in ethyl acetate and the resulting mixture was magnetically stirred at room temperature for 30 minutes. The reaction mixture was then neutralised with saturated sodium hydrogen carbonate, the organic phase separated and the aqueous layer was extracted with ethyl acetate . The combined organic phase were washed with brine and dried over anhydrous sodium sulfate. Evaporation of the solvent gave the titled methyl ester.
Analogously the following derivatives were prepared:
(E) -Methyl 2- (3-chlorobenzoyl) -1-amino-cyclopropane-l- carboxylate ;
(E) -Methyl 2- (3 -bromobenzoyl) -1-amino-cyclopropane-l- carboxylate;
(E) -Methyl 2- (3 -fluorobenzoyl) -1-amino-cyclopropane-l-
carboxylate; and
(E) -Methyl 2- (3 , 4 -difluorobenzoyl) - l-amino-cyclopropane- 1-carboxylate .
Example 27
Preparation of (E) -2- (3 , 4-dichlorobenzoyl) - 1 -amino- cyclopropane- 1-carboxylic acid.
1 N Lithium hydroxide monohyrate was added to a solution of (E) -Methyl 2- (3 , 4-dichlorobenzoyl) -1-amino-cyclopropane-l- carboxylate in dioxane and the resulting mixture was kept under magnetic stirring at room temperature overnight. The reaction mixture was then evaporated to dryness, the residue diluted with water and neutralised with 1 N hydrochloric acid. Ion exchange chromatography on Dowex 50x2 200 and elution with 10% pyridine yielded the titled compound.
Analogously the following derivatived were prepared:
(E) -2- (3 , 4 -difluorobenzoyl) -1-amino-cyclopropane- 1-carboxylic acid;
(E) -2- (3-chlorobenzoyl) -l-amino-cyclopropane- 1-carboxylic acid;
(E) -2- (3 -fluorobenzoyl) -1-amino-cyclopropane-l-carboxylic acid; and
(E) -2- (3 -bromobenzoyl) -1-amino-cyclopropane-l-carboxylic acid.
Example 28
Preparation of (E) -Methyl , 2- (3 , 4 -difluorobenzoyl) - cyclopropane- 1-carboxylate
A solution of E-cyclopropane-1 , 2 -dicarboxylate acid monomethyl ester (1 g, 6.9 mmol) in oxalylchloride (20 ml) was stirred under Argon atmosphere during 2 hours then concentrated under vacuum. To a solution of the resulting residue in o-
dichlorobenzene (4 ml) , under magneting stirring and Argon atmosphere at 0°C, aluminium chloride (2.76 g, 38.5 mmol) was added portion wise during 30'. After fifteen minute the reaction mixture was heated at 60°C for 90' and then poured into ice-hydrochloric acid 3N. The aqueous layer was extracted with ethyl acetate (4x50 ml) . The organic phases were combined washed with brine (1x50 ml), dried over sodium sulphate and concentrated under vacuo . The oil residue was purified on silica gel by means of flash chromatography. Using light petroleum and light petroleum/ethyl acetate 95:5 as eluent, 602 mg of methyl (E) -Methyl, 2- (3 , 4-difluorobenzoyl) -cyclopropane- 1-carboxylate were collected (yield 36%) .
XH-NMR (CDC13) δ: 1.6-1.7 (m, 2H, 3-CH2); 2.3-2.4 (m, 1H, 1-CH); 3.0-3.1 (m, 1H, 2-CH); 3.7 (s, 3H, COOCH3) ; 7.2-7.4 (m, 1H, 5'- CH) ; 7.8-7.9 (m, 2H, 6'-CH 2'-CH).
13C-NMR (CDCI3) δ: 17.9, 24.53; 25.68; 52.15; 117.35; 117.71; 125.31; 134.09; 147.84 (d); 151.13 (d) ; 152.83 (d) : 156.24 (d) ; 172.32; 194.36.
Analogously the following compounds can be prepared: (E) -Methyl, 2- (3 , 4-dichlorobenzoyl) -3 -methylene-cyclopropane-1- carboxylate . m.p.= 81°C
XH-NMR (CDCI3) δ: 3.1-3.2 (m, 1H, 1-CH); 3.7-3.8 (m, 4H, 2-CH COOCH3) ; 5.5-5.7 (d, 2H, 3 -exomethylene) ; 7.6 (d, 1H, 5'-CH, J0=8.5 Hz); 7.7 (dd, 1H, 6'-CH, J0=8.4 Hz Jm=2 Hz); 8.1 (d, 1H, 2' -CH, J„=2Hz) .
13C-NMR (CDCI3) δ: 25.65; 29.96; 52.18; 105.25; 127.36; 130.21; 130.70; 133.30; 136.00; 137.96; 169.51; 190.82.
(E) -Methyl , 2- (3 , 4-dichlorobenzoyl) -3,3 - dime thy 1- cyclopropane - 1-carboxylate. m.p.= 59-60°C
XH-NMR (CDCl3)δ: 1.2(s, 3H, 3α-CH3) ; 1.3 (t, 3H, COOCH2CH3) ; 1.4
(s, 3H, 3β-CH3) ; 2.5 (d, IH, 1-CH, Jtrans =5.7 Hz) ; 3.0 (d, IH, 2-CH, Jtrans= 5.7 Hz) ; 4.0-4.2 (m, 2H, COOCH2CH3) ; 7.4 (d, IH,
5'-CH, J0=8.4 Hz) ; 7.7 (dd, IH, 6'-CH, J0=δ .4 Hz Jm=2 Hz) ; 7.9
(d, IH, 2' -CH, Jm=2Hz) .
13C-NMR (CDCI3) δ: 14.16; 19.93; 20.20; 33.29; 33.59; 38.50; 60.78; 127.06; 130.01; 130.64; 133.27; 137.40; 137.58; 170.28; 193.47.
(E) -Methyl, 2- (3 , 4-dichlorobenzoyl) -3-methyl-cyclopropane-l- carboxylate .
XH-NMR (CDCI3) δ: 1.1-1.2 (d, 3H, 3-CH3) ; 2.0-2.2 ( , IH, 3- CH) ; 2.4-2.6 (m, IH, 2-CH) ; 3.0-3.3 (m, IH, 1-CH) ; 3.7 (s,3H, COOCH3; 7.5 (d, IH, 5'-CH, J0=8.4 Hz) ; 7.8-7.9 (dd, IH, 6' -CH, J0=8.4 Hz Jm=2 Hz) ; 8.0-8.1 (d, IH, 2'-CH, Jm=2Hz) .
(E) -Methyl , 2- (3 , 4-dichlorobenzoyl) -cyclopentane- 1-carboxylate .
^"H-NMR (CDCI3) δ: 1.6-2.2 (m, 6H, cyclopentane); 3.3-3.4 (m, IH,
1-CH); 3.6 (s, 3H, COOCH3) ; 3.9-4.1 (m, IH, 2-CH); 7.5 (d, IH, 5'-CH, J0=8.7 Hz); 7.7 (dd, IH, 6'-CH, J0=8.3 Hz Jm=2 Hz); 8.0 (d, IH, 2'CH, Jm=2Hz) .
13C-NMR (CDCI3) δ: 25.73; 30.49; 31.36; 46.16; 49.47; 51.86; 127.56; 130.56; 130.65; 133.29; 136.05; 137.61; 175.37; 198.80.
(E) -Methyl, 2- (3 , 4-dichlorobenzoyl) -cyclobutane -1 -carboxylate .
XH-NMR (CDCI3) δ: 2.1-2.3 (m, 4H cyclobutane); 3.4-3.6 (m, IH,
1-CH); 3.6 (s, 3H, COOCH3) ; 4.0-4.4 (m, IH, 2-CH); 7.4 (d, IH,
5'CH, J0=8.7 Hz); 7.7 (dd, IH, 6'-CH, J0=8.3 Hz Jm=2 Hz); 8.0 (d, IH, 2' -CH, Jm=2 Hz) .
Example 29
Preparation of (E) -2- (3, 4 -difluorobenzoyl ) -cyclopropane- 1- carboxylic acid
To a solution of methyl (E) -2 - (3 , 4 -difluorobenzoyl ) - cyclopropane- 1-carboxylate (522 mg, 2.17 mmol) in dioxane (7 ml), maintained under magnetic stirring, an aqueous solution (3 ml) of potassium hydroxide (182.5 mg, 3.26 mmol) was added. The resulting solution was stirred at room temperature during 20' then was diluted with water (30 ml) . The aqueous layer was extracted with ethyl acetate (3x10 ml), acidified with hydrochloric acid 3N and extxracted with ethyl acetate (3x20 ml) . These last organic phases are combined, washed with brine (1x10 ml) , dried over sodium sulphate and concentrated under vacuo . 471 mg of (E) -2- (3 , 4-difluorobenzoyl ) - cyclopropane- 1- carboxylic acid as a white solid were collected (yield 96%) . m.p. = 81-82°C
XH-NMR (CDCl3+CD3OD)δ: 1.6-1.7 (m, 2H, 3-CH2); 2.4-2.5 (m, IH, 1-CH); 3.1-3.3 (m, IH, 2-CH); 7.2-7.4 (m, IH, 5'-CH); 7.7 ( ,
2H, 6' -CH 2' -CH) ; 9.7 (bs, IH, COOH) .
13C-NMR (CDC13+CD30D) δ: 18.27; 24.38; 26.15; 38.97; 117.45; 117.80; 125.39; 133.91; 147.88 (d) ; 151.24 (d) ; 152.86(d) ; 156.36 (d) ; 177.96; 194.07.
Analogously the following compound can be prepared: (E) -2- (3 , 4-dichlorobenzoyl) -3 -methylene-cycloρropane-1- carboxylic acid. m.p.= 184°C dec.
^-N R (CDCI3+CD3OD) δ: 3.1-3.2 (m, IH, 1-CH) ; 3.7-3.8 (m, 4H, 2- CH) ; 5.5-5.8 (m, 2H, 3 -exomethylene , COOH) ; 7.6 (d, IH, 5' -CH, J0=8.5 Hz) ; 7.8 (dd, IH, 6' -CH, J0=8.4 HzJm=2Hz) ; 8.1 (d, IH, 2' -CH, Jm=2Hz) .
13C-NMR (CDCI3+CD3OD) δ: 25.94; 30.29; 105.57; 127.47; 130.42; 130.89; 133.55; 136.06; 138.33; 172.74; 191.29.
(E) -2 - (3 , 4-dichlorobenzoyl ) -3 , 3 -dimethyl -cyclopropane- 1- carboxylic acid, m.p. 148-150°C.
XH-NMR (CDCI3 + CD3OD) δ: 1.1 (s, 3H, 3α-CH3) ; 1.5 (s, 3H, 3β-CH3) ; 2.6 (d, IH, 1-CH, Jtrans = 5.7 Hz) ; 3.2 (d, IH, 2-CH, Jtrans=5.7 Hz) ; 4.6 (bs, IH, COOH) ; 8.0 (d, IH, 5' -CH, J0=8.4 Hz) ; 8.2 (dd, IH, 6' -CH, J0=8.4 Jm=2Hz) ; 8.5 (d, IH, 2' -CH, Jm=2 Hz) .
13C-NMR (CDC13+CD30D) δ: 19.94; 20.21; 27.89, 28.30; 33.44; 38.72; 127.09; 130.01; 130.69; 133.28; 137.37; 137.64; 172.95; 193.78.
(E) 2- (3 , 4-dichlorobenzoyl) -3 -methyl -cyclopropane- 1-carboxylic acid. m.p. = 129°C
XH-NMR (Acetone D6) δ: 1.0-1.1 (dd, 3H, 3-CH3) ; 2.0-2.2 (m, IH, 3-CH) ; 2.2-2.3 (m, IH, 2-CH) ; 3.1-3.2 (m, IH, 1-CH) ; 7.5 (d, IH, 5' -CH, J0=8.4 Hz) ; 7.9-8.0 (dd, IH, 6' -CH, J0=8.4 Hz Jm=2 Hz) ; 8.0-8.1 (d, IH, 2' -CH, Jm=2 Hz) ; 9.0 (bs, IH, COOH) .
13C-NMR (Acetone-Dg) δ: 11.03; 27.23; 28.81; 33.30; 128.71; 130.83; 131.82; 133.45; 137.66; 138.71; 173.17, 193.85.
(E) 2- (3 , 4-dichlorobenzoyl) -cyclobutane -1-carboxylic acid m.p.= 129-131°C
XH-NMR (CDCI3+CD3OD) δ: 2.1-2.4 (m, 4H cyclobutane); 3.5-3.7 ( , IH, 1-CH); 4.1-4.3 (m, IH, 2-CH); 4.9 (bs, IH, COOH); 7.5 (d, IH, 5'-CH, J0=8.4 Hz); 7.7 (dd, IH, 6'-CH, J0=8.4 Hz Jm=2 Hz); 8.0 (d, IH, 2'-CH, J„=2 Hz) .
13C-NMR (CDCI3+CD3OD) δ: 22.19; 23.23; 38.97; 44.30; 127.92; 130.84; 131.21; 133.71; 135.06; 138.23; 177.01; 197.63.
(E) -2- (3 , 4-dichlorobenzoyl) -cyclopentane-1-carboxylic acid m.p. = 86°C (dec . )
XH-N R (Acetone-Dg) δ: 1.6-2.2 (m, 6H, cyclopentane); 3.3-3.4 (m, IH, 1-CH); 4.0-4.1 (m, IH, 2-CH); 7.7 (d, IH, 5'-CH, J0=8.7 Hz); 7.9 (dd, IH, 6'-CH, J0=8.3 Hz Jm=2 Hz); 8.1 (d, IH, 2'-CH Jm=2 Hz) .
13C-NMR (Acetone-Dg) δ: 25.73; 30.49; 31.36; 46.16; 49.47; 127.56; 130.56; 130.65; 133.29; 136.05; 137.61; 177.07; 198.80.
Example 30
Preparation of (E) -2- (3 , 4-dichlorobenzoyl) -cyclopropane- 1- carboxamide
3.5g (12.82 mmol) of (E) -Methyl -2- (3 , 4-dichlorobenzoyl) - cyclopropane- 1-carboxylate were dissolved in dioxane (50 ml) and treated with 30% NH4OH (140 ml) for 3 days at room temperature .
The residue after evaporation was crystallized from i-propyl ether to give 1.6g of (E) -2- (3 , 4-dichlorobenzoyl) -cyclopropane - 1-carboxamide (51%) .
M.P. 188-191°C
Analogously the following compounds can be prepared:
(E) -2- (3 , 4-dichlorobenzoyl) -cyclopropane- 1-N-methylcarboxamide m.p. 127-129°C;
(E) -2- (3 , 4-dichlorobenzoyl) - cyclopropane -1-hydroxamic acid m.p. 61-62°C;
(E) -2- (3 , 4-dichlorobenzoyl) -cyclopropane-1-N-benzylcarboxamide m.p. 151-153°C; (E) -2- (3 , 4 -dichlorobenzoyl) -cyclopropane- 1-N-phenylcarboxamide m.p. 156-157°C;
(E) -2- (3 , 4 -dichlorobenzoyl) -cyclopropane-1-N- phenylsulfonylcarboxamide , m.p. 172-173°C.
Example 31
Capsule, each weighing 0.23 g and containing 50 mg of the active substance can be prepared as follows: Composition for 500 capsules: (E) -2- (3 , 4-dichlorobenzoyl) -cyclopropyl -
-1-carboxylic acid 25 g
Lactose 80 g
Corn starch 5 g
Magnesium stearate 5 g This formulation can be incapsulated in two hard gelatin capsules of two pieces, each with each capsule weighing 0.23 g.
Example 32 Intramuscular injection of 50 mg/ml
A pharmaceutical injectable composition can be manifactured dissolving 50 g (E) -2- (3 , 4-dichlorobenzoyl) -cyclopropyl-l- carboxylic acid in sterile propyleneglycol (1000 ml) and sealed in 1-5 ml ampoules.
Legend to Figure 1
IDO = Indolamineoxigenase
KYN = Kynurenine
KYN-OH = Kynurenine-3 -hydroxylase
KYNA = Kynurenic acid
3-OHAA = 3 -hydroxy anthranilic acid
KYNase = Kynureninase
QUIN = Quinolinic acid
3-HAO = 3 -hydroxy anthranilic acid deoxygenase
KAT = Kynurenine amino transferase
3-OHKYN = 3 -Hydroxy-kynurenine
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9705031.4A GB9705031D0 (en) | 1997-03-11 | 1997-03-11 | 2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivatives |
GB9705031 | 1997-03-11 | ||
PCT/EP1998/000883 WO1998040344A1 (en) | 1997-03-11 | 1998-02-16 | 2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6497998A true AU6497998A (en) | 1998-09-29 |
Family
ID=10809053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU64979/98A Abandoned AU6497998A (en) | 1997-03-11 | 1998-02-16 | 2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivatives |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0973720A1 (en) |
JP (1) | JP2001514634A (en) |
KR (1) | KR20000076096A (en) |
CN (1) | CN1252049A (en) |
AU (1) | AU6497998A (en) |
CA (1) | CA2283184A1 (en) |
EA (1) | EA199900809A1 (en) |
GB (1) | GB9705031D0 (en) |
HU (1) | HUP0001023A3 (en) |
IL (1) | IL131676A0 (en) |
NO (1) | NO994386L (en) |
PL (1) | PL335601A1 (en) |
TW (1) | TW407146B (en) |
WO (1) | WO1998040344A1 (en) |
ZA (1) | ZA981972B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1424333A1 (en) * | 2002-11-28 | 2004-06-02 | Newron Pharmaceuticals S.p.A. | Halothenoyl-cyclopropane-1-carboxylic acid derivatives |
EP1475385A1 (en) * | 2003-05-05 | 2004-11-10 | Newron Pharmaceuticals S.p.A. | Glycoside derivatives of 2-(3,4-dichlorobenzoyl)-cycopropane-1-carboxylic acid |
EP1475088A1 (en) * | 2003-05-05 | 2004-11-10 | Newron Pharmaceuticals S.p.A. | Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract |
CN104244939A (en) * | 2012-04-05 | 2014-12-24 | Chdi基金会股份有限公司 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
CN103373911B (en) * | 2012-04-27 | 2016-12-14 | 中国科学院上海有机化学研究所 | Single fluoro cyclopropanes compound and its preparation method and application |
CN104119246A (en) * | 2013-04-26 | 2014-10-29 | 中国科学院上海有机化学研究所 | Cyclopropane derivatives, and preparation method and application thereof |
JP2016536350A (en) | 2013-09-26 | 2016-11-24 | シーエイチディーアイ ファウンデーション,インコーポレーテッド | Kynurenin-3-monooxygenase inhibitor, pharmaceutical composition, and methods of use thereof |
US9938252B2 (en) | 2013-09-26 | 2018-04-10 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3655667A (en) * | 1968-04-04 | 1972-04-11 | Smith Kline French Lab | 1-(2-benzoylcyclopropylmethyl)-4-phenylpiperazines |
-
1997
- 1997-03-11 GB GBGB9705031.4A patent/GB9705031D0/en active Pending
-
1998
- 1998-02-16 IL IL13167698A patent/IL131676A0/en unknown
- 1998-02-16 AU AU64979/98A patent/AU6497998A/en not_active Abandoned
- 1998-02-16 EA EA199900809A patent/EA199900809A1/en unknown
- 1998-02-16 JP JP53912398A patent/JP2001514634A/en not_active Withdrawn
- 1998-02-16 CN CN98804144A patent/CN1252049A/en active Pending
- 1998-02-16 CA CA002283184A patent/CA2283184A1/en not_active Abandoned
- 1998-02-16 EP EP98910685A patent/EP0973720A1/en not_active Withdrawn
- 1998-02-16 HU HU0001023A patent/HUP0001023A3/en unknown
- 1998-02-16 PL PL98335601A patent/PL335601A1/en unknown
- 1998-02-16 KR KR1019997008184A patent/KR20000076096A/en not_active Application Discontinuation
- 1998-02-16 WO PCT/EP1998/000883 patent/WO1998040344A1/en not_active Application Discontinuation
- 1998-02-26 TW TW087102847A patent/TW407146B/en active
- 1998-03-09 ZA ZA981972A patent/ZA981972B/en unknown
-
1999
- 1999-09-10 NO NO994386A patent/NO994386L/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL335601A1 (en) | 2000-05-08 |
EA199900809A1 (en) | 2000-08-28 |
HUP0001023A2 (en) | 2000-09-28 |
TW407146B (en) | 2000-10-01 |
NO994386D0 (en) | 1999-09-10 |
JP2001514634A (en) | 2001-09-11 |
GB9705031D0 (en) | 1997-04-30 |
WO1998040344A1 (en) | 1998-09-17 |
CA2283184A1 (en) | 1998-09-17 |
ZA981972B (en) | 1998-09-09 |
KR20000076096A (en) | 2000-12-26 |
IL131676A0 (en) | 2001-03-19 |
HUP0001023A3 (en) | 2001-03-28 |
CN1252049A (en) | 2000-05-03 |
NO994386L (en) | 1999-11-02 |
EP0973720A1 (en) | 2000-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0662948B1 (en) | 2-amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and/or kynurenine-3-hydroxylase inhibiting activity | |
US6048896A (en) | 4-phenyl-4-oxo-2-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity | |
AU695852B2 (en) | Polyarylcarbamoylaza -and- carbamoylalkanedioic acids | |
JP3542599B2 (en) | Substituted (arylalkoxybenzyl) aminopropanamide derivatives and method for producing the same | |
US7531692B2 (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
AU6497998A (en) | 2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivatives | |
JP2001501179A (en) | N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid having kynurenine-3-hydroxylase inhibitory activity | |
AU1808401A (en) | Method for the stereoselective synthesis of cyclic amino acids | |
JP2003506317A (en) | LTA4 hydrolase inhibitor | |
US6133302A (en) | 5-(3-Phenyl-3-oxo-propyl)-1H-tetrazole derivatives | |
MXPA99008300A (en) | 2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivatives | |
US5973006A (en) | Fluoro-substituted benzoylpropionic acid derivatives | |
EP1656340B1 (en) | Processes for making 1-carbamoylcycloalkylcarboxylic acid compounds | |
EP0686145B1 (en) | New compounds | |
EP1001941A1 (en) | Fused heterocyclic compounds and their use as kynurenine-3-hydroxylase inhibitors | |
WO1999016771A1 (en) | Condensed benzothiopyranic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |